<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Research Foundation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23060793</article-id><article-id pub-id-type="pmc">3460347</article-id><article-id pub-id-type="doi">10.3389/fphar.2012.00172</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Nicotine, Auditory Sensory Memory, and <italic>sustained</italic> Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Knott</surname><given-names>Verner</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="author-notes" rid="fn001">*</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Dhrasti</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Millar</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>McIntosh</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>Derek</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blais</surname><given-names>Crystal</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ilivitsky</surname><given-names>Vadim</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Institute of Mental Health Research, University of Ottawa</institution><country>Ottawa, ON, Canada</country></aff><aff id="aff2"><sup>2</sup><institution>Neuroscience Program, Department of Cellular and Molecular Medicine, University of Ottawa</institution><country>Ottawa, ON, Canada</country></aff><aff id="aff3"><sup>3</sup><institution>School of Psychology, University of Ottawa</institution><country>Ottawa, ON, Canada</country></aff><aff id="aff4"><sup>4</sup><institution>Institute of Cognitive Science, Carleton University</institution><country>Ottawa, ON, Canada</country></aff><aff id="aff5"><sup>5</sup><institution>Royal Ottawa Mental Health Centre</institution><country>Ottawa, ON, Canada</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Psychology, Mount Saint Vincent University</institution><country>Halifax, NS, Canada</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Valentina Echeverria Moran, Bay Pines VA Medical Center, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Boris B. Quednow, University Hospital of Psychiatry, Switzerland; Jason B. Wu, Cedars-Sinai Medical Center, USA</p></fn><corresp id="fn001">*Correspondence: Verner Knott, Clinical Neuroelectrophysiology and Cognitive Research Laboratory, Institute of Mental Health Research, University of Ottawa, 1145 Carling Avenue, Ottawa, ON, Canada K1Z 7K4. e-mail: <email xlink:type="simple">verner.knott@theroyal.ca</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Pharmacology.</p></fn></author-notes><pub-date pub-type="epreprint"><day>16</day><month>7</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>3</volume><elocation-id>172</elocation-id><history><date date-type="received"><day>14</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Knott, Shah, Millar, McIntosh, Fisher, Blais and Ilivitsky.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><license-p>This is an open-access article distributed under the terms of the <uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</uri>, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</license-p></license></permissions><abstract><p><bold><offsets xml_i="5442" xml_f="5453" txt_i="11" txt_f="22">Background:</offsets></bold><offsets xml_i="5460" xml_f="5799" txt_i="22" txt_f="361"> The procognitive actions of the nicotinic acetylcholine receptor (nAChR) agonist nicotine are believed, in part, to motivate the excessive cigarette smoking in schizophrenia, a disorder associated with deficits in multiple cognitive domains, including low-level auditory sensory processes and higher-order attention-dependent operations. </offsets><bold><offsets xml_i="5805" xml_f="5816" txt_i="361" txt_f="372">Objectives:</offsets></bold><offsets xml_i="5823" xml_f="5827" txt_i="372" txt_f="376"> As </offsets><italic><offsets xml_i="5835" xml_f="5836" txt_i="376" txt_f="377">N</offsets></italic><offsets xml_i="5845" xml_f="5853" txt_i="377" txt_f="385">-methyl-</offsets><sc><offsets xml_i="5857" xml_f="5858" txt_i="385" txt_f="386">d</offsets></sc><offsets xml_i="5863" xml_f="6156" txt_i="386" txt_f="679">-aspartate receptor (NMDAR) hypofunction has been shown to contribute to these cognitive impairments, the primary aims of this healthy volunteer study were to: (a) to shed light on the separate and interactive roles of nAChR and NMDAR systems in the modulation of auditory sensory memory (and </offsets><italic><offsets xml_i="6164" xml_f="6173" txt_i="679" txt_f="688">sustained</offsets></italic><offsets xml_i="6182" xml_f="6395" txt_i="688" txt_f="901"> attention), as indexed by the auditory event-related brain potential – mismatch negativity (MMN), and (b) to examine how these effects are moderated by a predisposition to auditory hallucinations/delusions (HD). </offsets><bold><offsets xml_i="6401" xml_f="6409" txt_i="901" txt_f="909">Methods:</offsets></bold><offsets xml_i="6416" xml_f="6749" txt_i="909" txt_f="1242"> In a randomized, double-blind, placebo-controlled design involving a low intravenous dose of ketamine (0.04 mg/kg) and a 4 mg dose of nicotine gum, MMN, and performance on a rapid visual information processing (RVIP) task of sustained attention were examined in 24 healthy controls psychometrically stratified as being lower (L-HD, </offsets><italic><offsets xml_i="6757" xml_f="6758" txt_i="1242" txt_f="1243">n</offsets></italic><offsets xml_i="6767" xml_f="6810" txt_i="1243" txt_f="1286"> = 12) or higher (H-HD) for HD propensity. </offsets><bold><offsets xml_i="6816" xml_f="6824" txt_i="1286" txt_f="1294">Results:</offsets></bold><offsets xml_i="6831" xml_f="7074" txt_i="1294" txt_f="1537"> Ketamine significantly slowed MMN, and reduced MMN in H-HD, with amplitude attenuation being blocked by the co-administration of nicotine. Nicotine significantly enhanced response speed [reaction time (RT)] and accuracy (increased % hits and </offsets><italic><offsets xml_i="7082" xml_f="7083" txt_i="1537" txt_f="1538">d</offsets></italic><offsets xml_i="7092" xml_f="7138" txt_i="1538" txt_f="1584">′ and reduced false alarms) on the RVIP, with </offsets><italic><offsets xml_i="7146" xml_f="7175" txt_i="1584" txt_f="1613">improved performance accuracy</offsets></italic><offsets xml_i="7184" xml_f="7263" txt_i="1613" txt_f="1692"> being prevented when nicotine was administered with ketamine. Both % hits and </offsets><italic><offsets xml_i="7271" xml_f="7272" txt_i="1692" txt_f="1693">d</offsets></italic><offsets xml_i="7281" xml_f="7352" txt_i="1693" txt_f="1764">′, as well as RT were poorer in H-HD (vs. L-HD) and while hit rate and </offsets><italic><offsets xml_i="7360" xml_f="7361" txt_i="1764" txt_f="1765">d</offsets></italic><offsets xml_i="7370" xml_f="7442" txt_i="1765" txt_f="1837">′ was increased by nicotine in H-HD, RT was slowed by ketamine in L-HD. </offsets><bold><offsets xml_i="7448" xml_f="7460" txt_i="1837" txt_f="1849">Conclusions:</offsets></bold><offsets xml_i="7467" xml_f="7595" txt_i="1849" txt_f="1977"> Nicotine alleviated ketamine-induced sensory memory impairment and improved attention, particularly in individuals prone to HD.</offsets></p></abstract><kwd-group><kwd>nicotine</kwd><kwd>nicotinic acetylcholine receptor</kwd><kwd><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor</kwd><kwd>sensory memory</kwd><kwd>mismatch negativity</kwd><kwd>attention</kwd><kwd>rapid visual information processing task</kwd><kwd>schizophrenia</kwd></kwd-group><counts><fig-count count="7"></fig-count><table-count count="1"></table-count><equation-count count="0"></equation-count><ref-count count="136"></ref-count><page-count count="13"></page-count><word-count count="11857"></word-count></counts></article-meta></front><body><sec><title><offsets xml_i="8192" xml_f="8204" txt_i="1985" txt_f="1997">Introduction</offsets></title><p><offsets xml_i="8215" xml_f="8742" txt_i="1998" txt_f="2525">In patients with schizophrenia, the cardinal clinical (positive and negative) symptoms are, to variable degrees, accompanied by a wide range of neurocognitive impairments, particularly in the domains of attention and working memory. The various cognitive deficits are neither state-related nor specific to subtypes of the illness, but are considered as enduring features which remain relatively constant over the course of the disease and are at the very core of the dysfunction in schizophrenia patients (Eleväg and Goldberg, </offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8774" xml_f="8778" txt_i="2525" txt_f="2529">2000</offsets></xref><offsets xml_i="8785" xml_f="8798" txt_i="2529" txt_f="2542">; Heinrichs, </offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="8830" xml_f="8834" txt_i="2542" txt_f="2546">2005</offsets></xref><offsets xml_i="8841" xml_f="9208" txt_i="2546" txt_f="2913">). As cognitive impairments in schizophrenia are highly correlated with functional (social and vocational) outcome, and both are relatively unaffected by dopamine-based antipsychotic drugs, pharmacotherapeutic initiatives are focusing on alternative molecular mechanisms as promising pharmacological targets for improving cognitive abilities in this disorder (Green, </offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="9240" xml_f="9244" txt_i="2913" txt_f="2917">2007</offsets></xref><offsets xml_i="9251" xml_f="9275" txt_i="2917" txt_f="2941">; Tcheremissine et al., </offsets><xref ref-type="bibr" rid="B118"><offsets xml_i="9308" xml_f="9312" txt_i="2941" txt_f="2945">2012</offsets></xref><offsets xml_i="9319" xml_f="9321" txt_i="2945" txt_f="2947">).</offsets></p><p><offsets xml_i="9328" xml_f="9558" txt_i="2948" txt_f="3178">Converging evidence from preclinical and human research points to the therapeutic potential of drugs targeted at nicotinic acetylcholine receptors (nAChRs) in the treatment of schizophrenia cognition (Ochoa and Lasalde-Dominicci, </offsets><xref ref-type="bibr" rid="B92"><offsets xml_i="9590" xml_f="9594" txt_i="3178" txt_f="3182">2007</offsets></xref><offsets xml_i="9601" xml_f="9621" txt_i="3182" txt_f="3202">; Evans and Drobes, </offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="9653" xml_f="9657" txt_i="3202" txt_f="3206">2009</offsets></xref><offsets xml_i="9664" xml_f="9686" txt_i="3206" txt_f="3228">; D’Souza and Markou, </offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="9718" xml_f="9722" txt_i="3228" txt_f="3232">2011</offsets></xref><offsets xml_i="9729" xml_f="9825" txt_i="3232" txt_f="3328">). nAChRs are strongly implicated in normal cognitive information processes (Mansvelder et al., </offsets><xref ref-type="bibr" rid="B80"><offsets xml_i="9857" xml_f="9861" txt_i="3328" txt_f="3332">2006</offsets></xref><offsets xml_i="9868" xml_f="10145" txt_i="3332" txt_f="3609">). Nicotine, the primary psychoactive chemical in tobacco smoke, is a prototypical nAChR agonist and the increased prevalence of smoking in schizophrenia (∼70–80%) compared to the general population (∼20%) has been interpreted as a form of self-medication (Kumari and Postman, </offsets><xref ref-type="bibr" rid="B69"><offsets xml_i="10177" xml_f="10181" txt_i="3609" txt_f="3613">2005</offsets></xref><offsets xml_i="10188" xml_f="10200" txt_i="3613" txt_f="3625">; Winterer, </offsets><xref ref-type="bibr" rid="B134"><offsets xml_i="10233" xml_f="10237" txt_i="3625" txt_f="3629">2010</offsets></xref><offsets xml_i="10244" xml_f="10393" txt_i="3629" txt_f="3778">), perhaps to compensate for reduced expression of nAChRs observed in post-mortem hippocampal and cortical brain regions of patients (Breese et al., </offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10425" xml_f="10429" txt_i="3778" txt_f="3782">2000</offsets></xref><offsets xml_i="10436" xml_f="10439" txt_i="3782" txt_f="3785">). </offsets><italic><offsets xml_i="10447" xml_f="10700" txt_i="3785" txt_f="4038">Although recent evidence of nicotine interacting with schizophrenia risk genes with regards to the expression of endophenotypes such as sensory gating may suggest that smoking might act as a causal factor for schizophrenia and related cognitive deficits</offsets></italic><offsets xml_i="10709" xml_f="10727" txt_i="4038" txt_f="4056"> (Quednow et al., </offsets><xref ref-type="bibr" rid="B99"><offsets xml_i="10759" xml_f="10763" txt_i="4056" txt_f="4060">2012</offsets></xref><offsets xml_i="10770" xml_f="10928" txt_i="4060" txt_f="4218">), meta-analysis has shown significant enhancing effects of acute nicotine on multiple cognitive domains in healthy smokers and non-smokers (Heishman et al., </offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="10960" xml_f="10964" txt_i="4218" txt_f="4222">2010</offsets></xref><offsets xml_i="10971" xml_f="11342" txt_i="4222" txt_f="4593">). Although null findings have been reported in the cognitive literature, acute doses of nicotine in animal models of schizophrenia and in non-smoking and smoking schizophrenia patients also transiently improve elementary pre-attentive sensory processing deficits as well as performance impairments in higher-order attention and working memory tasks (Olincy and Stevens, </offsets><xref ref-type="bibr" rid="B93"><offsets xml_i="11374" xml_f="11378" txt_i="4593" txt_f="4597">2007</offsets></xref><offsets xml_i="11385" xml_f="11401" txt_i="4597" txt_f="4613">; Radek et al., </offsets><xref ref-type="bibr" rid="B102"><offsets xml_i="11434" xml_f="11438" txt_i="4613" txt_f="4617">2010</offsets></xref><offsets xml_i="11445" xml_f="11447" txt_i="4617" txt_f="4619">).</offsets></p><p><offsets xml_i="11454" xml_f="11497" txt_i="4620" txt_f="4663">Neurochemical models of schizophrenia have </offsets><italic><offsets xml_i="11505" xml_f="11515" txt_i="4663" txt_f="4673">implicated</offsets></italic><offsets xml_i="11524" xml_f="11565" txt_i="4673" txt_f="4714"> glutamatergic mechanisms in general and </offsets><italic><offsets xml_i="11573" xml_f="11574" txt_i="4714" txt_f="4715">N</offsets></italic><offsets xml_i="11583" xml_f="11591" txt_i="4715" txt_f="4723">-methyl-</offsets><sc><offsets xml_i="11595" xml_f="11596" txt_i="4723" txt_f="4724">d</offsets></sc><offsets xml_i="11601" xml_f="12084" txt_i="4724" txt_f="5207">-aspartate receptors (NMDARs) in particular. NMDAR-type glutamate receptors are widely distributed throughout the brain and single sub-anesthetic doses of NMDAR antagonists, such as phencyclidine or ketamine, induce transient and reversible neurochemical, symptomatic and neurocognitive aspects of the disorder in healthy controls, with information processing deficits being observed not only in higher cortical regions, but also in subcortical systems and sensory cortices (Javitt, </offsets><xref ref-type="bibr" rid="B49"><offsets xml_i="12116" xml_f="12120" txt_i="5207" txt_f="5211">2010</offsets></xref><offsets xml_i="12127" xml_f="12143" txt_i="5211" txt_f="5227">; Adell et al., </offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="12174" xml_f="12178" txt_i="5227" txt_f="5231">2012</offsets></xref><offsets xml_i="12185" xml_f="12527" txt_i="5231" txt_f="5573">). Over the past decade, bottom-up sensory processing deficits have become increasingly well documented in schizophrenia, co-existing with top-down, more complex forms of cognitive impairments and mirroring the pattern of deficits seen with NMDAR antagonists, thus supporting a NMDAR hypofunction model of the disease (Kantrowitz and Javitt, </offsets><xref ref-type="bibr" rid="B54"><offsets xml_i="12559" xml_f="12563" txt_i="5573" txt_f="5577">2010</offsets></xref><offsets xml_i="12570" xml_f="12572" txt_i="5577" txt_f="5579">).</offsets></p><p><offsets xml_i="12579" xml_f="12953" txt_i="5580" txt_f="5954">Disturbance in low-level sensory problems in the auditory system is a robust cognitive deficit in schizophrenia patients and is strongly indexed by impaired generation of an event-related brain potential (ERP) component – the mismatch negativity (MMN). Generated within the primary auditory cortex and receiving contributions from frontal cortical generators (Rinne et al., </offsets><xref ref-type="bibr" rid="B106"><offsets xml_i="12986" xml_f="12990" txt_i="5954" txt_f="5958">2000</offsets></xref><offsets xml_i="12997" xml_f="13504" txt_i="5958" txt_f="6465">), the MMN is automatically elicited (at ∼150–200 ms) in an auditory “oddball” paradigm in response to infrequent changes (i.e., deviants, such as shifts in sound pitch, intensity, duration, location, or pattern) in a repetitive stream of auditory stimuli. Presumed to reflect the stored representations of the characteristics of auditory stimuli (for seconds to minutes), MMN is an index of auditory sensory (“echoic”) memory, a pre-attentive component of the brain working memory system (Naatanen et al., </offsets><xref ref-type="bibr" rid="B88"><offsets xml_i="13536" xml_f="13540" txt_i="6465" txt_f="6469">2011</offsets></xref><offsets xml_i="13547" xml_f="13689" txt_i="6469" txt_f="6611">). Impaired MMN generation, which is specific to schizophrenia (vs. other psychiatric disorders), is well established (Naatanen and Kahkonen, </offsets><xref ref-type="bibr" rid="B87"><offsets xml_i="13721" xml_f="13725" txt_i="6611" txt_f="6615">2009</offsets></xref><offsets xml_i="13732" xml_f="13804" txt_i="6615" txt_f="6687">), with a mean effect size of ∼1 d across studies (Umbricht and Krljes, </offsets><xref ref-type="bibr" rid="B127"><offsets xml_i="13837" xml_f="13841" txt_i="6687" txt_f="6691">2005</offsets></xref><offsets xml_i="13848" xml_f="14057" txt_i="6691" txt_f="6900">). Neither typical nor atypical antipsychotics affect the amplitude or latency of the ERP, and deficits in MMN generation have been reported in both clozapine- and risperidone-treated patients (Schall et al., </offsets><xref ref-type="bibr" rid="B108"><offsets xml_i="14090" xml_f="14094" txt_i="6900" txt_f="6904">1998</offsets></xref><offsets xml_i="14101" xml_f="14120" txt_i="6904" txt_f="6923">; Umbricht et al., </offsets><xref ref-type="bibr" rid="B125"><offsets xml_i="14153" xml_f="14157" txt_i="6923" txt_f="6927">1998</offsets></xref><offsets xml_i="14164" xml_f="14193" txt_i="6927" txt_f="6956">; Umbricht and Vollenweider, </offsets><xref ref-type="bibr" rid="B129"><offsets xml_i="14226" xml_f="14230" txt_i="6956" txt_f="6960">1999</offsets></xref><offsets xml_i="14237" xml_f="14253" txt_i="6960" txt_f="6976">; Kasai et al., </offsets><xref ref-type="bibr" rid="B55"><offsets xml_i="14285" xml_f="14289" txt_i="6976" txt_f="6980">2002</offsets></xref><offsets xml_i="14296" xml_f="14298" txt_i="6980" txt_f="6982">).</offsets></p><p><italic><offsets xml_i="14313" xml_f="14314" txt_i="6983" txt_f="6984">N</offsets></italic><offsets xml_i="14323" xml_f="14331" txt_i="6984" txt_f="6992">-methyl-</offsets><sc><offsets xml_i="14335" xml_f="14336" txt_i="6992" txt_f="6993">d</offsets></sc><offsets xml_i="14341" xml_f="14483" txt_i="6993" txt_f="7135">-aspartate receptor antagonists have dose-dependently blocked the MMN response recorded in auditory primary cortex in animals (Javitt et al., </offsets><xref ref-type="bibr" rid="B53"><offsets xml_i="14515" xml_f="14519" txt_i="7135" txt_f="7139">1994</offsets></xref><offsets xml_i="14526" xml_f="14528" txt_i="7139" txt_f="7141">, </offsets><xref ref-type="bibr" rid="B52"><offsets xml_i="14560" xml_f="14564" txt_i="7141" txt_f="7145">1996</offsets></xref><offsets xml_i="14571" xml_f="14639" txt_i="7145" txt_f="7213">) and have diminished the MMN in healthy controls (Umbricht et al., </offsets><xref ref-type="bibr" rid="B128"><offsets xml_i="14672" xml_f="14676" txt_i="7213" txt_f="7217">2000</offsets></xref><offsets xml_i="14683" xml_f="14716" txt_i="7217" txt_f="7250">; Kreitschmann-Andermahr et al., </offsets><xref ref-type="bibr" rid="B64"><offsets xml_i="14748" xml_f="14752" txt_i="7250" txt_f="7254">2001</offsets></xref><offsets xml_i="14759" xml_f="14778" txt_i="7254" txt_f="7273">; Heekeren et al., </offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="14810" xml_f="14814" txt_i="7273" txt_f="7277">2008</offsets></xref><offsets xml_i="14821" xml_f="15037" txt_i="7277" txt_f="7493">). Nicotine effects on MMN on the other hand have been relatively consistent with increased amplitude and shorter latencies to tone pitch deviants being observed in patients with Alzheimer’ disease (Engeland et al., </offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="15069" xml_f="15073" txt_i="7493" txt_f="7497">2002</offsets></xref><offsets xml_i="15080" xml_f="15183" txt_i="7497" txt_f="7600">), whereas in healthy controls, nicotine has augmented MMN amplitudes to pitch (Harkrider and Hedrick, </offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="15215" xml_f="15219" txt_i="7600" txt_f="7604">2005</offsets></xref><offsets xml_i="15226" xml_f="15269" txt_i="7604" txt_f="7647">), inter-stimulus interval (Martin et al., </offsets><xref ref-type="bibr" rid="B82"><offsets xml_i="15301" xml_f="15305" txt_i="7647" txt_f="7651">2009</offsets></xref><offsets xml_i="15312" xml_f="15355" txt_i="7651" txt_f="7694">), and duration deviants (Baldeweg et al., </offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="15386" xml_f="15390" txt_i="7694" txt_f="7698">2006</offsets></xref><offsets xml_i="15397" xml_f="15644" txt_i="7698" txt_f="7945">), with the two former MMN effects being observed both in smokers and non-smokers, while the latter effect was shown only in smokers. The latency of the pitch-MMN has also been shortened with nicotine administration in non-smokers (Inauri et al., </offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="15676" xml_f="15680" txt_i="7945" txt_f="7949">2005</offsets></xref><offsets xml_i="15687" xml_f="15852" txt_i="7949" txt_f="8114">), who have also evidenced a shortened latency and an increased amplitude of the pitch-MMN with an acute dose of the selective nAChR agonist AZD3480 (Dunbar et al., </offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="15884" xml_f="15888" txt_i="8114" txt_f="8118">2007</offsets></xref><offsets xml_i="15895" xml_f="15979" txt_i="8118" txt_f="8202">), as well as an amplitude increase of the visual MMN with nicotine (Fisher et al., </offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="16011" xml_f="16015" txt_i="8202" txt_f="8206">2010</offsets></xref><offsets xml_i="16022" xml_f="16024" txt_i="8206" txt_f="8208">).</offsets></p><p><offsets xml_i="16031" xml_f="16326" txt_i="8209" txt_f="8504">In the first of two studies in schizophrenia patients, acute nicotine treatment did not alter the pitch-MMN amplitude in non-smoking patients and controls, but in the latter group, it shortened MMN latency relative both to placebo and to the MMN latency seen in the patient group (Inami et al., </offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="16358" xml_f="16362" txt_i="8504" txt_f="8508">2007</offsets></xref><offsets xml_i="16369" xml_f="16569" txt_i="8508" txt_f="8708">). In the second study, conducted in our laboratory, nicotine also increased duration- (but not pitch) MMN in smoking patients, normalizing their amplitude relative to control smokers (Dulude et al., </offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="16601" xml_f="16605" txt_i="8708" txt_f="8712">2010</offsets></xref><offsets xml_i="16612" xml_f="16710" txt_i="8712" txt_f="8810">). These effects were not associated with tobacco withdrawal symptoms or antipsychotic medication.</offsets></p><p><offsets xml_i="16717" xml_f="16801" txt_i="8811" txt_f="8895">Nicotine modulates the release of neurotransmitters other than acetylcholine (e.g., </offsets><italic><offsets xml_i="16809" xml_f="16817" txt_i="8895" txt_f="8903">dopamine</offsets></italic><offsets xml_i="16826" xml_f="16854" txt_i="8903" txt_f="8931">, GABA, norepinephrine, and </offsets><italic><offsets xml_i="16862" xml_f="16871" txt_i="8931" txt_f="8940">glutamate</offsets></italic><offsets xml_i="16880" xml_f="17067" txt_i="8940" txt_f="9127">), with presynaptic nAChRs facilitating NMDAR-mediated glutamatergic neurotransmission in a multitude of brain regions including (but not limited to) the prefrontal cortex (Lambe et al., </offsets><xref ref-type="bibr" rid="B70"><offsets xml_i="17099" xml_f="17103" txt_i="9127" txt_f="9131">2003</offsets></xref><offsets xml_i="17110" xml_f="17113" txt_i="9131" txt_f="9134">). </offsets><italic><offsets xml_i="17121" xml_f="17180" txt_i="9134" txt_f="9193">nAChRs are heavily expressed in the primary auditory cortex</offsets></italic><offsets xml_i="17189" xml_f="17204" txt_i="9193" txt_f="9208"> (Soto et al., </offsets><xref ref-type="bibr" rid="B114"><offsets xml_i="17237" xml_f="17241" txt_i="9208" txt_f="9212">2006</offsets></xref><offsets xml_i="17248" xml_f="17250" txt_i="9212" txt_f="9214">) </offsets><italic><offsets xml_i="17258" xml_f="17348" txt_i="9214" txt_f="9304">where nicotine has enhanced tone-evoked physiological sensitivity through NMDAR activation</offsets></italic><offsets xml_i="17357" xml_f="17370" txt_i="9304" txt_f="9317"> (Metherate, </offsets><xref ref-type="bibr" rid="B84"><offsets xml_i="17402" xml_f="17406" txt_i="9317" txt_f="9321">2004</offsets></xref><offsets xml_i="17413" xml_f="17531" txt_i="9321" txt_f="9439">). Previous preclinical cognitive studies of nAChR-NMDAR interactions have shown mixed findings (Timofeeva and Levin, </offsets><xref ref-type="bibr" rid="B124"><offsets xml_i="17564" xml_f="17568" txt_i="9439" txt_f="9443">2011</offsets></xref><offsets xml_i="17575" xml_f="17750" txt_i="9443" txt_f="9618">), with some reporting nicotine blockade of the disruptive pre-attentive (sensorimotor gating), attentional, and mnemonic effects of NMDAR antagonists (Thompson and Winsaver, </offsets><xref ref-type="bibr" rid="B120"><offsets xml_i="17783" xml_f="17787" txt_i="9618" txt_f="9622">1986</offsets></xref><offsets xml_i="17794" xml_f="17810" txt_i="9622" txt_f="9638">; Terry et al., </offsets><xref ref-type="bibr" rid="B119"><offsets xml_i="17843" xml_f="17847" txt_i="9638" txt_f="9642">2002</offsets></xref><offsets xml_i="17854" xml_f="17875" txt_i="9642" txt_f="9663">; Rezvani and Levin, </offsets><xref ref-type="bibr" rid="B105"><offsets xml_i="17908" xml_f="17912" txt_i="9663" txt_f="9667">2003</offsets></xref><offsets xml_i="17919" xml_f="17943" txt_i="9667" txt_f="9691">; Spieleway and Markov, </offsets><xref ref-type="bibr" rid="B115"><offsets xml_i="17976" xml_f="17980" txt_i="9691" txt_f="9695">2004</offsets></xref><offsets xml_i="17987" xml_f="18007" txt_i="9695" txt_f="9715">; Andreasen et al., </offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="18038" xml_f="18042" txt_i="9715" txt_f="9719">2006</offsets></xref><offsets xml_i="18049" xml_f="18070" txt_i="9719" txt_f="9740">; Levin and Rezvani, </offsets><xref ref-type="bibr" rid="B73"><offsets xml_i="18102" xml_f="18106" txt_i="9740" txt_f="9744">2006</offsets></xref><offsets xml_i="18113" xml_f="18131" txt_i="9744" txt_f="9762">; Rezvani et al., </offsets><xref ref-type="bibr" rid="B104"><offsets xml_i="18164" xml_f="18168" txt_i="9762" txt_f="9766">2008</offsets></xref><offsets xml_i="18175" xml_f="18314" txt_i="9766" txt_f="9905">), while others reported no interactions, or observed a potentiation of impairments induced with NMDAR antagonist treatment (Levin et al., </offsets><xref ref-type="bibr" rid="B75"><offsets xml_i="18346" xml_f="18350" txt_i="9905" txt_f="9909">2003</offsets></xref><offsets xml_i="18357" xml_f="18359" txt_i="9909" txt_f="9911">, </offsets><xref ref-type="bibr" rid="B74"><offsets xml_i="18391" xml_f="18395" txt_i="9911" txt_f="9915">2005</offsets></xref><offsets xml_i="18402" xml_f="18423" txt_i="9915" txt_f="9936">; Rezvani and Levin, </offsets><xref ref-type="bibr" rid="B105"><offsets xml_i="18456" xml_f="18460" txt_i="9936" txt_f="9940">2003</offsets></xref><offsets xml_i="18467" xml_f="18484" txt_i="9940" txt_f="9957">; Quarta et al., </offsets><xref ref-type="bibr" rid="B98"><offsets xml_i="18516" xml_f="18520" txt_i="9957" txt_f="9961">2007</offsets></xref><offsets xml_i="18527" xml_f="18547" txt_i="9961" txt_f="9981">; Rasmussen et al., </offsets><xref ref-type="bibr" rid="B103"><offsets xml_i="18580" xml_f="18584" txt_i="9981" txt_f="9985">2008</offsets></xref><offsets xml_i="18591" xml_f="18739" txt_i="9985" txt_f="10133">). In the few human studies, the NMDAR antagonist memantine did not oppose the smoking-induced improvements in sustained attention (Jackson et al., </offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="18771" xml_f="18775" txt_i="10133" txt_f="10137">2009</offsets></xref><offsets xml_i="18782" xml_f="18985" txt_i="10137" txt_f="10340">), and in our work with ketamine, nicotine moderation of the arousal and attentional modulating actions of this NMDAR antagonist were found to be dependent on smoker vs. non-smoker status (Knott et al., </offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="19017" xml_f="19021" txt_i="10340" txt_f="10344">2006</offsets></xref><offsets xml_i="19028" xml_f="19030" txt_i="10344" txt_f="10346">, </offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="19062" xml_f="19066" txt_i="10346" txt_f="10350">2011</offsets></xref><offsets xml_i="19073" xml_f="19075" txt_i="10350" txt_f="10352">).</offsets></p><p><offsets xml_i="19082" xml_f="19325" txt_i="10353" txt_f="10596">Mismatch negativity deficits in schizophrenia are highly correlated with cognitive and functional outcome and as the NMDAR antagonist model has shown predictive ability for a range of novel treatments that have reached clinical trials (Large, </offsets><xref ref-type="bibr" rid="B71"><offsets xml_i="19357" xml_f="19361" txt_i="10596" txt_f="10600">2007</offsets></xref><offsets xml_i="19368" xml_f="20109" txt_i="10600" txt_f="11341">), the human ketamine model, together with the use of putative endophenotypes such as MMN, offer a good opportunity to study new drugs with novel and distinct cognitive enhancing mechanisms that go beyond dopamine transmission. In the present study, the first to investigate the role of NMDAR-mediated glutamatergic neurotransmission in nicotine-modulated sensory memory, the separate and combined actions of nicotine and ketamine were examined with respect to auditory MMN. In addition, as NMDAR antagonism also impairs sustained attentional performance, typically slowing response speed and reducing accuracy in continuous performance tasks (CPT), a performance pattern similar to that observed in schizophrenia patients (Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="20141" xml_f="20145" txt_i="11341" txt_f="11345">1999</offsets></xref><offsets xml_i="20152" xml_f="20170" txt_i="11345" txt_f="11363">; Krystal et al., </offsets><xref ref-type="bibr" rid="B66"><offsets xml_i="20202" xml_f="20207" txt_i="11363" txt_f="11368">2005a</offsets></xref><offsets xml_i="20214" xml_f="20215" txt_i="11368" txt_f="11369">,</offsets><xref ref-type="bibr" rid="B67"><offsets xml_i="20247" xml_f="20248" txt_i="11369" txt_f="11370">b</offsets></xref><offsets xml_i="20255" xml_f="20450" txt_i="11370" txt_f="11565">), the study also examined the effects of these drugs and their interactions on the Rapid Visual Information Processing (RVIP) task, a CPT with putative endophenotypic sensitivity (Hilti et al., </offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="20482" xml_f="20486" txt_i="11565" txt_f="11569">2010</offsets></xref><offsets xml_i="20493" xml_f="20795" txt_i="11569" txt_f="11871">). As it is unclear as to whether ketamine-induced cognitive impairments reflect the direct effects of ketamine or are secondary to the induced schizophrenia-like clinical symptoms, we followed our previous studies and administered a sub-perceptual, non-psychotomimetic dose of ketamine (Knott et al., </offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="20827" xml_f="20831" txt_i="11871" txt_f="11875">2006</offsets></xref><offsets xml_i="20838" xml_f="20840" txt_i="11875" txt_f="11877">, </offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="20872" xml_f="20876" txt_i="11877" txt_f="11881">2011</offsets></xref><offsets xml_i="20883" xml_f="20885" txt_i="11881" txt_f="11883">).</offsets></p><p><offsets xml_i="20892" xml_f="21289" txt_i="11884" txt_f="12281">Although the human ketamine model in healthy volunteers is well established and allows for the investigation of neurotransmitter systems participating in NMDAR-mediated cognitive deficiency, these findings may not necessarily be relevant to cognitive impairment in schizophrenia. Confounding factors (prior or concomitant drug treatment, chronicity, lack of cooperation, lower education) make the </offsets><italic><offsets xml_i="21297" xml_f="21304" txt_i="12281" txt_f="12288">in vivo</offsets></italic><offsets xml_i="21313" xml_f="22282" txt_i="12288" txt_f="13257"> study of ketamine-drug interactions in schizophrenia difficult. However, the use of healthy surrogate populations (e.g., unaffected relatives of patients or people with schizotypal personality features), defined as groups that feature a component of the main disease process but do not have the fully developed condition – is gaining momentum as a potential methodology for detecting novel drug treatment for schizophrenia and as such may be relevant for capturing NMDAR-nicotinic interactions regulating cognitive endophenotypes of schizophrenia. In this approach, schizophrenia is viewed as an extreme of normally distributed cognitive functions and, for people who express some of the phenotype without the full disease (psychoses), their endophenotypes (such as MMN and RVIP) are thought to be more sensitive to drug effects and/or neurochemical disturbances than unselected healthy volunteers because they share the same elements of the disorder (Koychev et al., </offsets><xref ref-type="bibr" rid="B63"><offsets xml_i="22314" xml_f="22318" txt_i="13257" txt_f="13261">2011</offsets></xref><offsets xml_i="22325" xml_f="22692" txt_i="13261" txt_f="13628">). One phenotype, auditory hallucinations (AHs), is strongly associated with psychotic disorders such as schizophrenia but is also observed in other clinical and non-clinical groups (i.e., are “trans-diagnostic”). Increasingly, AHs are being investigated in non-psychotic conditions with cognitive and behavioral paradigms developed for schizophrenia (Waters et al., </offsets><xref ref-type="bibr" rid="B131"><offsets xml_i="22725" xml_f="22729" txt_i="13628" txt_f="13632">2012</offsets></xref><offsets xml_i="22736" xml_f="22921" txt_i="13632" txt_f="13817">). As the trait that makes humans prone to AHs appears to be related to brain areas involved in auditory stimuli processing/speech perception (i.e., auditory cortex; Kuhn and Gallinat, </offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="22953" xml_f="22957" txt_i="13817" txt_f="13821">2010</offsets></xref><offsets xml_i="22964" xml_f="23187" txt_i="13821" txt_f="14044">), the same brain regions participating in MMN generation, and as schizophrenia patients with AHs (vs. those without AHs) have exhibited reduced MMN-indexed auditory sensory memory in our laboratory studies (Fisher et al., </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="23219" xml_f="23223" txt_i="14044" txt_f="14048">2008</offsets></xref><offsets xml_i="23230" xml_f="23232" txt_i="14048" txt_f="14050">, </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="23264" xml_f="23268" txt_i="14050" txt_f="14054">2011</offsets></xref><offsets xml_i="23275" xml_f="23277" txt_i="14054" txt_f="14056">, </offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="23309" xml_f="23314" txt_i="14056" txt_f="14061">2012a</offsets></xref><offsets xml_i="23321" xml_f="23322" txt_i="14061" txt_f="14062">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="23354" xml_f="23355" txt_i="14062" txt_f="14063">b</offsets></xref><offsets xml_i="23362" xml_f="23559" txt_i="14063" txt_f="14260">), this present investigation examined the effects of ketamine, nicotine, and their interactions in healthy volunteers psychometrically assessed as varying in hallucination/delusion (HD) proneness.</offsets></p><p><offsets xml_i="23566" xml_f="23861" txt_i="14261" txt_f="14556">It was expected that individuals with higher (vs. lower) HD proneness would exhibit reduced MMN and RVIP performance, be more susceptible to the detrimental effects of ketamine, and be more responsive to the enhancing actions of nicotine when administered alone and in combination with ketamine.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="23912" xml_f="23933" txt_i="14558" txt_f="14579">Materials and Methods</offsets></title><sec><title><offsets xml_i="23953" xml_f="23971" txt_i="14580" txt_f="14598">Study participants</offsets></title><p><offsets xml_i="23982" xml_f="24394" txt_i="14599" txt_f="15011">A sample of 24 participants (10 males, 14 females) was selected from a larger group of 38 healthy volunteers recruited from advertisements in local media and universities. All potential participants were screened via a semi-structured interview for psychiatric disorders (including alcohol/drug abuse) and general health, and were also assessed with the Family Instrument for Genetic Studies (Nurnberger et al., </offsets><xref ref-type="bibr" rid="B91"><offsets xml_i="24426" xml_f="24430" txt_i="15011" txt_f="15015">1994</offsets></xref><offsets xml_i="24437" xml_f="24614" txt_i="15015" txt_f="15192">) to rule out those with psychiatric disorders within first-degree relatives. They were also administered the Bell Object Relations and Reality Testing Inventory (BORRTI; Bell, </offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="24645" xml_f="24649" txt_i="15192" txt_f="15196">1992</offsets></xref><offsets xml_i="24656" xml_f="25236" txt_i="15196" txt_f="15776">), a 90-item, self-report true-false pencil-and-paper questionnaire: 45 items assessing object relations, and the other 45 reality testing, with the latter yielding three subscale factors (Reality of Distortions, Uncertainty of Perceptions, and Hallucinations and Delusions), which are thought to identify those with a predisposition for psychotic symptoms. Only the HD subscale was used in this study. HD scores correlate significantly with the Hallucinatory Behavior and Unused Thought Content scales of the widely used Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, </offsets><xref ref-type="bibr" rid="B95"><offsets xml_i="25268" xml_f="25272" txt_i="15776" txt_f="15780">1962</offsets></xref><offsets xml_i="25279" xml_f="25415" txt_i="15780" txt_f="15916">) and HD is the only subscale of the BORRTI on which high scores are specific to schizophrenia vs. other criterion groups (Bell et al., </offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="25447" xml_f="25451" txt_i="15916" txt_f="15920">1985</offsets></xref><offsets xml_i="25458" xml_f="25477" txt_i="15920" txt_f="15939">). Standardized HD </offsets><italic><offsets xml_i="25485" xml_f="25486" txt_i="15939" txt_f="15940">t</offsets></italic><offsets xml_i="25495" xml_f="25732" txt_i="15940" txt_f="16177"> scores of the total sample ranged from 30 to 67 (mean = 46.5) and those individuals with the 12 lowest (L-HD) scores (mean = 36.9, range 30–42) and the 12 highest (H-HD) scores (mean = 56.3, range 52–67) were selected for this study. A </offsets><italic><offsets xml_i="25740" xml_f="25741" txt_i="16177" txt_f="16178">t</offsets></italic><offsets xml_i="25750" xml_f="26774" txt_i="16178" txt_f="17202"> score of 60 or more is indicative of a deficit and three of the H-HD group exhibited scores of 61, 61, and 67. L-HD and H-HD groups did not differ with respect to their scores on the Reality of Distortions and Uncertainty of Perception subscale factors. Groups were similar with respect to age, gender, and non-smoker/smoker status (L-HD: seven non-smokers, five smokers; H-HD: six non-smokers, six smokers). All the non-smokers had not smoked a cigarette in the past year, and the smoking characteristics of the smoking in the two groups was similar, with smokers smoking on average for 7.8 years (range 4–12) and smoking a mean of 16.8 cigarettes/day (range 15–20). None of these participants reported a personal or first-degree family psychiatric history, use of medications or a serious medical problem, and none exhibited abnormal results during a physical examination (with electrocardiogram) or with routine laboratory tests (complete blood count, blood chemistry, urine analysis, and urine toxicology for drug use).</offsets></p><p><offsets xml_i="26781" xml_f="26948" txt_i="17203" txt_f="17370">The study was approved by the Research Ethics Board of the Royal Ottawa Health Care Group and all participants signed an informed consent prior to study participation.</offsets></p></sec><sec><title><offsets xml_i="26970" xml_f="26989" txt_i="17372" txt_f="17391">Experimental design</offsets></title><p><offsets xml_i="27000" xml_f="27717" txt_i="17392" txt_f="18109">The study involved four test sessions couched within a double-blind, placebo-controlled, cross-over design with two parallel groups, L-HD and H-HD. Each session involved the intravenous infusion of ketamine (KI) or a comparable placebo (PI) as well as oral administration (gum) of nicotine (NG) or a comparable placebo (PG). Two of the four test sessions involved a KI and in the remaining two sessions participants received a PI. Also, in one of the KI and PI sessions, participants were pretreated with NG, and in the other two (KI and PI) sessions they were pretreated with PG. Order of the four treatments (PG–PI, PG–KI, NG–PI, NG–KI) was counterbalanced and sessions were separated by a minimum one-day interval.</offsets></p></sec><sec><title><offsets xml_i="27739" xml_f="27757" txt_i="18111" txt_f="18129">Session procedures</offsets></title><p><offsets xml_i="27768" xml_f="28479" txt_i="18130" txt_f="18841">In each of the four test sessions, participants arrived at the laboratory (08:00 a.m.) following overnight (beginning 12:00 a.m.) abstinence from food, drugs, alcohol, caffeine, and cigarettes. Smoking abstinence was verified by an expired air carbon monoxide (CO) reading, which was required to be below 5 parts per million (ppm). Following insertion of an antecubital intravenous line, a 45-min adaptation period and EEG electrode placement, participants were administered either NG or PG, and after a 30-min nicotine absorption period, KI or PI was initiated along with the RVIP task and simultaneous ERP recordings for MMN. Vital signs were assessed both before drug treatment and at the end of the session.</offsets></p></sec><sec><title><offsets xml_i="28501" xml_f="28520" txt_i="18843" txt_f="18862">Drug administration</offsets></title><sec><title><offsets xml_i="28540" xml_f="28548" txt_i="18863" txt_f="18871">Nicotine</offsets></title><p><offsets xml_i="28559" xml_f="28670" txt_i="18872" txt_f="18983">An oral dose of nicotine was administered in the form of nicotine polacrilex gum, providing delivery primarily </offsets><italic><offsets xml_i="28678" xml_f="28681" txt_i="18983" txt_f="18986">via</offsets></italic><offsets xml_i="28690" xml_f="28727" txt_i="18986" txt_f="19023"> buccal absorption (Hukkanen et al., </offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="28759" xml_f="28763" txt_i="19023" txt_f="19027">2005</offsets></xref><offsets xml_i="28770" xml_f="29111" txt_i="19027" txt_f="19368">). A 4 mg Nicorette Plus (Hoechst Roussell) gum piece or matching placebo was chewed (with nose plugs, to help reduce any possible sensory impact differences between nicotine and placebo) over a 25-min period according to manufacturer guidelines, with participants using an audiotape to instruct them to bite the gum twice per minute and to </offsets><italic><offsets xml_i="29119" xml_f="29123" txt_i="19368" txt_f="19372">park</offsets></italic><offsets xml_i="29132" xml_f="29530" txt_i="19372" txt_f="19770"> the gum (i.e., inside the mouth between teeth and cheeks) after each bite. An additional 5-min absorption period, involving the chewing of a strong mint gum to help disguise any placebo vs. nicotine flavor differences, followed the gum chewing so that peak blood levels from the subsequent infusion of ketamine coincided with slower rising blood nicotine concentrations, which typically exhibit a </offsets><italic><offsets xml_i="29538" xml_f="29539" txt_i="19770" txt_f="19771">T</offsets></italic><sub><offsets xml_i="29553" xml_f="29556" txt_i="19771" txt_f="19774">max</offsets></sub><offsets xml_i="29562" xml_f="29642" txt_i="19774" txt_f="19854"> of ∼30-min and are expected to range between 10 and 17 ng/ml (Hukkanen et al., </offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="29674" xml_f="29678" txt_i="19854" txt_f="19858">2005</offsets></xref><offsets xml_i="29685" xml_f="29803" txt_i="19858" txt_f="19976">). Plasma levels of nicotine were not assessed. The elimination half-life of plasma nicotine is approximately 120 min.</offsets></p></sec><sec><title><offsets xml_i="29825" xml_f="29833" txt_i="19978" txt_f="19986">Ketamine</offsets></title><p><offsets xml_i="29844" xml_f="30103" txt_i="19987" txt_f="20246">Human ketamine studies of acute psychoses typically involve systemic infusions of ketamine at dose levels well below the 1–2 mg/kg dose range used in human anesthesia, either by administering a constant dose (0.5 mg/kg) over a ∼60-min period (Krystal et al., </offsets><xref ref-type="bibr" rid="B65"><offsets xml_i="30135" xml_f="30139" txt_i="20246" txt_f="20250">1994</offsets></xref><offsets xml_i="30146" xml_f="30204" txt_i="20250" txt_f="20308">), or by administering an initial bolus (Malhotra et al., </offsets><xref ref-type="bibr" rid="B79"><offsets xml_i="30236" xml_f="30240" txt_i="20308" txt_f="20312">1996</offsets></xref><offsets xml_i="30247" xml_f="30283" txt_i="20312" txt_f="20348">) or loading dose (Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="30315" xml_f="30319" txt_i="20348" txt_f="20352">1999</offsets></xref><offsets xml_i="30326" xml_f="30688" txt_i="20352" txt_f="20714">), both followed by infusion of a maintenance dose of ketamine to achieve steady state ketamine blood levels over a ∼60-min period. As loading doses of 0.27 and 0.08 mg/kg have produced marked and mild psychotomimetic-like reactions, respectively, with no subjective effects or measurable plasma ketamine levels being observed with 0.024 mg/kg (Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="30720" xml_f="30724" txt_i="20714" txt_f="20718">1999</offsets></xref><offsets xml_i="30731" xml_f="30908" txt_i="20718" txt_f="20895">), this study utilized an intermediate low loading dose of 0.04 mg/kg, but no maintenance dose, with the aim of avoiding the experience of schizophrenia-like clinical symptoms. </offsets><italic><offsets xml_i="30916" xml_f="31027" txt_i="20895" txt_f="21006">Although there are significant relations between MMN Amplitudes and psychoses-like symptoms induced by ketamine</offsets></italic><offsets xml_i="31036" xml_f="31055" txt_i="21006" txt_f="21025"> (Umbricht et al., </offsets><xref ref-type="bibr" rid="B126"><offsets xml_i="31088" xml_f="31092" txt_i="21025" txt_f="21029">2002</offsets></xref><offsets xml_i="31099" xml_f="31102" txt_i="21029" txt_f="21032">), </offsets><italic><offsets xml_i="31110" xml_f="31219" txt_i="21032" txt_f="21141">our use of a relatively low dose allows us to study the effects of ketamine independent of psychotic symptoms</offsets></italic><offsets xml_i="31228" xml_f="31570" txt_i="21141" txt_f="21483">. An automated pump apparatus (Imed Gemini PC-1) infused 0.04 mg/kg ketamine hydrochloride or placebo [saline (0.9% sodium chloride) solution] over a 10-min period in order to maximize safety. This dose level, previously used in our laboratory, had been associated with arousal EEG, and cognitive changes in healthy volunteers (Knott et al., </offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="31602" xml_f="31606" txt_i="21483" txt_f="21487">2006</offsets></xref><offsets xml_i="31613" xml_f="31615" txt_i="21487" txt_f="21489">, </offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="31647" xml_f="31651" txt_i="21489" txt_f="21493">2011</offsets></xref><offsets xml_i="31658" xml_f="31822" txt_i="21493" txt_f="21657">) and produced ketamine blood levels (25–37 mg/ml) that equated with levels seen in a prior study that administered a 0.08 mg/kg dose of ketamine (Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="31854" xml_f="31858" txt_i="21657" txt_f="21661">1999</offsets></xref><offsets xml_i="31865" xml_f="32083" txt_i="21661" txt_f="21879">). Although not able to be assessed in all the study participants due to prohibitive costs, gas chromatography (National Medical Services, Philadelphia, PA, USA) carried out on five plasma samples obtained from the PG–</offsets><italic><offsets xml_i="32091" xml_f="32092" txt_i="21879" txt_f="21880">M</offsets></italic><offsets xml_i="32101" xml_f="32240" txt_i="21880" txt_f="22019"> = 31 ng/ml). These ketamine levels approximate the average ketamine level reported with the 0.08 mg/kg dose of ketamine (Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="32272" xml_f="32276" txt_i="22019" txt_f="22023">1999</offsets></xref><offsets xml_i="32283" xml_f="32285" txt_i="22023" txt_f="22025">).</offsets></p></sec></sec><sec><title><offsets xml_i="32313" xml_f="32330" txt_i="22028" txt_f="22045">Study assessments</offsets></title><p><offsets xml_i="32341" xml_f="32546" txt_i="22046" txt_f="22251">In order to minimize attention to the auditory stimuli eliciting the MMN, these ERPs are typically acquired while participants are engaged in a secondary visual task, which in this case, was the RVIP task.</offsets></p><sec><title><offsets xml_i="32562" xml_f="32575" txt_i="22252" txt_f="22265">RVIP paradigm</offsets></title><p><offsets xml_i="32586" xml_f="32648" txt_i="22266" txt_f="22328">Employing the original RVIP paradigm of Wesnes and Warburton (</offsets><xref ref-type="bibr" rid="B132"><offsets xml_i="32681" xml_f="32685" txt_i="22328" txt_f="22332">1984</offsets></xref><offsets xml_i="32692" xml_f="33080" txt_i="22332" txt_f="22720">), participants viewed 50-ms duration single digits (1–9) presented (black on white) in the center of a monitor at a fixed rate of 110 digits/min, the average inter-stimulus interval being 545 ms and ranging between 445 and 645 ms. Button presses were required on the detection of targets, which were defined as the third of three consecutive odd digits. Over the 12-min task, a total of </offsets><italic><offsets xml_i="33088" xml_f="33092" txt_i="22720" txt_f="22724">1320</offsets></italic><offsets xml_i="33101" xml_f="33110" txt_i="22724" txt_f="22733"> digits, </offsets><italic><offsets xml_i="33118" xml_f="33139" txt_i="22733" txt_f="22754">including 120 targets</offsets></italic><offsets xml_i="33148" xml_f="33730" txt_i="22754" txt_f="23336"> (10 per min) were presented, with each target sequence being separated by a minimum of five digits. Volunteers were instructed to respond (with right index finger) as quickly and accurately as possible and performance measures included: the number of correct responses (expressed as % hits), with correct responses being defined as a button press to the third digit of each target triad within 100–1000 ms post-stimulus onset; the number (%) of incorrect or false alarm (FA) responses, defined as button presses to non-target stimuli, and reaction times (RT) of correct responses. </offsets><italic><offsets xml_i="33738" xml_f="33922" txt_i="23336" txt_f="23520">In addition, signal detection methodology was used to equally weight hits and FAs into a single measure (d′), which is considered to be a purer index of perceptual accuracy/sensitivity</offsets></italic><offsets xml_i="33931" xml_f="33957" txt_i="23520" txt_f="23546"> (Macmillan and Creelman, </offsets><xref ref-type="bibr" rid="B78"><offsets xml_i="33989" xml_f="33993" txt_i="23546" txt_f="23550">1997</offsets></xref><offsets xml_i="34000" xml_f="34137" txt_i="23550" txt_f="23687">). Response measures were separated into three successive time blocks of 4-min each to assess performance changes with drugs across time.</offsets></p></sec><sec><title><offsets xml_i="34159" xml_f="34171" txt_i="23689" txt_f="23701">MMN paradigm</offsets></title><p><offsets xml_i="34182" xml_f="34727" txt_i="23702" txt_f="24247">Auditory stimuli eliciting the MMN during ERP recordings consisted of a total of 1200, 80 dB tones (50 ms duration 10 ms rise/decay time) presented binaurally through headphones (80 dB sound pressure level) with a stimulus onset asynchrony of 545 ms (ranging between 445 and 645 ms) and between individual RVIP stimuli; resulting in no temporal overlap of the two stimulus modalities. Ten percent of the tones (deviants) were 100 Hz and were randomly presented among the standard tones (1000 Hz). Electrical activity was recorded from frontal (F</offsets><italic><sub><offsets xml_i="34740" xml_f="34741" txt_i="24247" txt_f="24248">z</offsets></sub></italic><offsets xml_i="34756" xml_f="34769" txt_i="24248" txt_f="24261">), central (C</offsets><italic><sub><offsets xml_i="34782" xml_f="34783" txt_i="24261" txt_f="24262">z</offsets></sub></italic><offsets xml_i="34798" xml_f="34816" txt_i="24262" txt_f="24280">), and parietal (P</offsets><italic><sub><offsets xml_i="34829" xml_f="34830" txt_i="24280" txt_f="24281">z</offsets></sub></italic><offsets xml_i="34845" xml_f="34867" txt_i="24281" txt_f="24303">) midline scalp sites </offsets><italic><offsets xml_i="34875" xml_f="34882" txt_i="24303" txt_f="24310">using a</offsets></italic><offsets xml_i="34891" xml_f="34907" txt_i="24310" txt_f="24326"> linked earlobe </offsets><italic><offsets xml_i="34915" xml_f="34924" txt_i="24326" txt_f="24335">reference</offsets></italic><offsets xml_i="34933" xml_f="34935" txt_i="24335" txt_f="24337">. </offsets><italic><offsets xml_i="34943" xml_f="35114" txt_i="24337" txt_f="24508">Although choice of reference site may potentially alter outcomes, ketamine-induced reductions in MMN have been observed with a variety of references, including linked ears</offsets></italic><offsets xml_i="35123" xml_f="35146" txt_i="24508" txt_f="24531"> (Gunduz-Bruce et al., </offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="35178" xml_f="35182" txt_i="24531" txt_f="24535">2012</offsets></xref><offsets xml_i="35189" xml_f="35191" txt_i="24535" txt_f="24537">) </offsets><italic><offsets xml_i="35199" xml_f="35218" txt_i="24537" txt_f="24556">and linked mastoids</offsets></italic><offsets xml_i="35227" xml_f="35246" txt_i="24556" txt_f="24575"> (Umbricht et al., </offsets><xref ref-type="bibr" rid="B128"><offsets xml_i="35279" xml_f="35283" txt_i="24575" txt_f="24579">2000</offsets></xref><offsets xml_i="35290" xml_f="35293" txt_i="24579" txt_f="24582">). </offsets><italic><offsets xml_i="35301" xml_f="35327" txt_i="24582" txt_f="24608">Recordings were also taken</offsets></italic><offsets xml_i="35336" xml_f="35356" txt_i="24608" txt_f="24628"> from orbital sites </offsets><italic><offsets xml_i="35364" xml_f="35367" txt_i="24628" txt_f="24631">and</offsets></italic><offsets xml_i="35376" xml_f="36159" txt_i="24631" txt_f="25411"> amplifier bandpass filters and EEG sampling rate set at 0.1–40 Hz and 250 Hz, respectively. ERP processing included epoch segmentation (500 ms, beginning 50 ms pre-stimulus onset), ocular correction, artifacting (eliminating ocular corrected epochs with EEG &gt; 100 μV), baseline correction, and separate averaging of standard and deviant epochs. As with the RVIP data, averages were separated into three equal time blocks, with each block containing 400 stimuli (40 deviants). There were no significant differences between the study conditions in terms of the number of epochs comprising standard and deviant averages and all deviant averages contained a minimum of 30 stimuli. MMNs were derived by digital point-by-point subtraction of standard waveforms from deviant waveforms. </offsets><italic><offsets xml_i="36167" xml_f="36253" txt_i="25411" txt_f="25497">Since out own work found frontal MMN in schizophrenia to be effected by acute nicotine</offsets></italic><offsets xml_i="36262" xml_f="36279" txt_i="25497" txt_f="25514"> (Dulude et al., </offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="36311" xml_f="36315" txt_i="25514" txt_f="25518">2010</offsets></xref><offsets xml_i="36322" xml_f="36324" txt_i="25518" txt_f="25520">) </offsets><italic><offsets xml_i="36332" xml_f="36446" txt_i="25520" txt_f="25634">and as ketamine-induced reductions in MMN in healthy volunteers was evidenced only at frontal (vs. temporal) sites</offsets></italic><offsets xml_i="36455" xml_f="36473" txt_i="25634" txt_f="25652"> (Schmidt et al., </offsets><xref ref-type="bibr" rid="B110"><offsets xml_i="36506" xml_f="36511" txt_i="25652" txt_f="25657">2012a</offsets></xref><offsets xml_i="36518" xml_f="36521" txt_i="25657" txt_f="25660">), </offsets><italic><offsets xml_i="36529" xml_f="36532" txt_i="25660" txt_f="25663">the</offsets></italic><offsets xml_i="36541" xml_f="36565" txt_i="25663" txt_f="25687"> MMN was measured from F</offsets><italic><sub><offsets xml_i="36578" xml_f="36579" txt_i="25687" txt_f="25688">z</offsets></sub></italic><offsets xml_i="36594" xml_f="36652" txt_i="25688" txt_f="25746">, the site of maximal amplitude. Based on grand averages, </offsets><italic><offsets xml_i="36660" xml_f="36673" txt_i="25746" txt_f="25759">MMN amplitude</offsets></italic><offsets xml_i="36682" xml_f="36869" txt_i="25759" txt_f="25946"> was defined as the peak negative voltage (relative to pre-stimulus baseline) in an 80–220 ms window. Latency (ms) was measured as the time (from stimulus onset) to reach peak negativity.</offsets></p></sec></sec><sec><title><offsets xml_i="36897" xml_f="36917" txt_i="25949" txt_f="25969">Statistical analysis</offsets></title><p><offsets xml_i="36928" xml_f="36960" txt_i="25970" txt_f="26002">Performance measures (hits, FA, </offsets><italic><offsets xml_i="36968" xml_f="36969" txt_i="26002" txt_f="26003">d</offsets></italic><offsets xml_i="36978" xml_f="37404" txt_i="26003" txt_f="26429">′, RT) were subjected to separate split-plot ANOVAs with one between-group factor (HD, two levels) and three within-group factors (gum, two levels; drug, two levels; time block, three levels). Similar ANOVAs were carried out with the ERP measures (MMN amplitude and latency). Greenhouse–Geisser corrections were applied where appropriate to compensate for violations of sphericity assumed with univariate ANOVAs. Significant (</offsets><italic><offsets xml_i="37412" xml_f="37413" txt_i="26429" txt_f="26430">p</offsets></italic><offsets xml_i="37422" xml_f="37525" txt_i="26430" txt_f="26530"> &lt; 0.05) main or interaction effects were followed up with Bonferroni adjusted pairwise comparisons.</offsets></p><p><italic><offsets xml_i="37540" xml_f="37920" txt_i="26531" txt_f="26911">Exploration of relationships between MMN and sustained attention were examined with Pearson r correlations between MMN amplitude and d′ (collapsed across groups and time blocks) using placebo data (i.e., PG plus PI condition) as well as change score data, derived by subtracting values in the placebo condition (PG–PI) from values derived in each of the three non-placebo sessions</offsets></italic><offsets xml_i="37929" xml_f="37930" txt_i="26911" txt_f="26912">.</offsets></p></sec></sec><sec><title><offsets xml_i="37958" xml_f="37965" txt_i="26915" txt_f="26922">Results</offsets></title><sec><title><offsets xml_i="37985" xml_f="37999" txt_i="26923" txt_f="26937">Effects on MMN</offsets></title><p><offsets xml_i="38010" xml_f="38271" txt_i="26938" txt_f="27199">Robust MMN amplitudes to pitch deviants were shown in each of the four test sessions and in each of the three time blocks within each session. No significant main effects were observed for drug, gum, group, or time block but a significant group × drug × block (</offsets><italic><offsets xml_i="38279" xml_f="38280" txt_i="27199" txt_f="27200">F</offsets></italic><offsets xml_i="38289" xml_f="38299" txt_i="27200" txt_f="27210"> = 4.05, d</offsets><italic><offsets xml_i="38307" xml_f="38308" txt_i="27210" txt_f="27211">f</offsets></italic><offsets xml_i="38317" xml_f="38327" txt_i="27211" txt_f="27221"> = 2, 44, </offsets><italic><offsets xml_i="38335" xml_f="38336" txt_i="27221" txt_f="27222">p</offsets></italic><offsets xml_i="38345" xml_f="38594" txt_i="27222" txt_f="27471"> = 0.031) interaction was demonstrated for amplitudes. Although exhibiting a general amplitude reduction with KI, planned comparisons showed that compared to placebo, KI (vs. PI) significantly reduced MMN only during time block 3 in the H-HD group (</offsets><italic><offsets xml_i="38602" xml_f="38603" txt_i="27471" txt_f="27472">p</offsets></italic><offsets xml_i="38612" xml_f="38719" txt_i="27472" txt_f="27579"> = 0.038). In addition, the MMN amplitude of the H-HD group during time block 3 was significantly smaller (</offsets><italic><offsets xml_i="38727" xml_f="38728" txt_i="27579" txt_f="27580">p</offsets></italic><offsets xml_i="38737" xml_f="38792" txt_i="27580" txt_f="27635"> = 0.05) than that of the L-HD group during KI (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="38822" xml_f="38823" txt_i="27635" txt_f="27636">1</offsets></xref><offsets xml_i="38830" xml_f="38832" txt_i="27636" txt_f="27638">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="38873" xml_f="38881" txt_i="27639" txt_f="27647">Figure 1</offsets></label><caption><p><bold><offsets xml_i="38907" xml_f="39005" txt_i="27647" txt_f="27745">Effects of placebo and ketamine infusion (collapsed across placebo and nicotine gum) on frontal (F</offsets><italic><offsets xml_i="39013" xml_f="39014" txt_i="27745" txt_f="27746">z</offsets></italic><offsets xml_i="39023" xml_f="39116" txt_i="27746" txt_f="27839">) mean (± SE) MMN amplitudes of L-HD and H-HD participants in the three time blocks (B1–B3; *</offsets><italic><offsets xml_i="39124" xml_f="39125" txt_i="27839" txt_f="27840">p</offsets></italic><offsets xml_i="39134" xml_f="39145" txt_i="27840" txt_f="27848"> &lt; 0.05)</offsets></bold><offsets xml_i="39152" xml_f="39153" txt_i="27848" txt_f="27849">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g001"></graphic></fig><p><offsets xml_i="39228" xml_f="39296" txt_i="27850" txt_f="27918">Follow-up analysis of a significant group × drug × gum interaction (</offsets><italic><offsets xml_i="39304" xml_f="39305" txt_i="27918" txt_f="27919">F</offsets></italic><offsets xml_i="39314" xml_f="39325" txt_i="27919" txt_f="27930"> = 3.945, d</offsets><italic><offsets xml_i="39333" xml_f="39334" txt_i="27930" txt_f="27931">f</offsets></italic><offsets xml_i="39343" xml_f="39353" txt_i="27931" txt_f="27941"> = 1, 22, </offsets><italic><offsets xml_i="39361" xml_f="39362" txt_i="27941" txt_f="27942">p</offsets></italic><offsets xml_i="39371" xml_f="39510" txt_i="27942" txt_f="28081"> = 0.049) showed a significant ketamine effect in the H-HD group. More specifically, when administered with PG, KI (vs. PI) significantly (</offsets><italic><offsets xml_i="39518" xml_f="39519" txt_i="28081" txt_f="28082">p</offsets></italic><offsets xml_i="39528" xml_f="39597" txt_i="28082" txt_f="28151"> = 0.004) attenuated MMN amplitudes of the H-HD participants (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="39627" xml_f="39628" txt_i="28151" txt_f="28152">2</offsets></xref><offsets xml_i="39635" xml_f="39782" txt_i="28152" txt_f="28299">). Additionally, in this same condition when KI was combined with PG, the H-HD exhibited significantly smaller MMN amplitudes than the L-HD group (</offsets><italic><offsets xml_i="39790" xml_f="39791" txt_i="28299" txt_f="28300">p</offsets></italic><offsets xml_i="39800" xml_f="40048" txt_i="28300" txt_f="28548"> = 0.004). In the H-HD group, KI did not attenuate MMN when it was administered with NG (i.e., nicotine blocked KI effects on MMN) and MMN was shown to be significantly smaller when KI was combined with PG compared to when it was combined with NG (</offsets><italic><offsets xml_i="40056" xml_f="40057" txt_i="28548" txt_f="28549">p</offsets></italic><offsets xml_i="40066" xml_f="40076" txt_i="28549" txt_f="28559"> = 0.007).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="40117" xml_f="40125" txt_i="28560" txt_f="28568">Figure 2</offsets></label><caption><p><bold><offsets xml_i="40151" xml_f="40334" txt_i="28568" txt_f="28751">Grand averaged waveforms showing MMN changes (collapsed across time blocks and L-HD and H-HD groups) with ketamine and placebo infusions when combined with nicotine and placebo gum (*</offsets><italic><offsets xml_i="40342" xml_f="40343" txt_i="28751" txt_f="28752">p</offsets></italic><offsets xml_i="40352" xml_f="40363" txt_i="28752" txt_f="28760"> &lt; 0.05)</offsets></bold><offsets xml_i="40370" xml_f="40371" txt_i="28760" txt_f="28761">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g002"></graphic></fig><p><offsets xml_i="40446" xml_f="40536" txt_i="28762" txt_f="28852">In addition to amplitude, latency of MMN was slightly but significantly affected by drug (</offsets><italic><offsets xml_i="40544" xml_f="40545" txt_i="28852" txt_f="28853">F</offsets></italic><offsets xml_i="40554" xml_f="40564" txt_i="28853" txt_f="28863"> = 4.38, d</offsets><italic><offsets xml_i="40572" xml_f="40573" txt_i="28863" txt_f="28864">f</offsets></italic><offsets xml_i="40582" xml_f="40592" txt_i="28864" txt_f="28874"> = 1, 22, </offsets><italic><offsets xml_i="40600" xml_f="40601" txt_i="28874" txt_f="28875">p</offsets></italic><offsets xml_i="40610" xml_f="40682" txt_i="28875" txt_f="28947"> = 0.048), with KI resulting in a slowing of MMN relative to PI (Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="40712" xml_f="40713" txt_i="28947" txt_f="28948">3</offsets></xref><offsets xml_i="40720" xml_f="40722" txt_i="28948" txt_f="28950">).</offsets></p><fig id="F3" position="float"><label><offsets xml_i="40763" xml_f="40771" txt_i="28951" txt_f="28959">Figure 3</offsets></label><caption><p><bold><offsets xml_i="40797" xml_f="40936" txt_i="28959" txt_f="29098">Effects of placebo and ketamine infusion (collapsed across gum conditions, time blocks, and L-HD and H-HD groups) on mean (± SE) frontal (F</offsets><italic><offsets xml_i="40944" xml_f="40945" txt_i="29098" txt_f="29099">z</offsets></italic><offsets xml_i="40954" xml_f="40970" txt_i="29099" txt_f="29115">) MMN latency (*</offsets><italic><offsets xml_i="40978" xml_f="40979" txt_i="29115" txt_f="29116">p</offsets></italic><offsets xml_i="40988" xml_f="40999" txt_i="29116" txt_f="29124"> &lt; 0.05)</offsets></bold><offsets xml_i="41006" xml_f="41007" txt_i="29124" txt_f="29125">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g003"></graphic></fig></sec><sec><title><offsets xml_i="41097" xml_f="41112" txt_i="29127" txt_f="29142">Effects on RVIP</offsets></title><p><offsets xml_i="41123" xml_f="41212" txt_i="29143" txt_f="29232">Response accuracy as expressed by % hits varied significantly in relation to time block (</offsets><italic><offsets xml_i="41220" xml_f="41221" txt_i="29232" txt_f="29233">F</offsets></italic><offsets xml_i="41230" xml_f="41240" txt_i="29233" txt_f="29243"> = 5.27, d</offsets><italic><offsets xml_i="41248" xml_f="41249" txt_i="29243" txt_f="29244">f</offsets></italic><offsets xml_i="41258" xml_f="41268" txt_i="29244" txt_f="29254"> = 2, 44, </offsets><italic><offsets xml_i="41276" xml_f="41277" txt_i="29254" txt_f="29255">p</offsets></italic><offsets xml_i="41286" xml_f="41321" txt_i="29255" txt_f="29290"> = 0.01), with hits being reduced (</offsets><italic><offsets xml_i="41329" xml_f="41330" txt_i="29290" txt_f="29291">p</offsets></italic><offsets xml_i="41339" xml_f="41366" txt_i="29291" txt_f="29318"> = 0.01) in time blocks 2 (</offsets><italic><offsets xml_i="41374" xml_f="41375" txt_i="29318" txt_f="29319">M</offsets></italic><offsets xml_i="41384" xml_f="41413" txt_i="29319" txt_f="29348"> = 79.94%, SE ± 4.98) and 3 (</offsets><italic><offsets xml_i="41421" xml_f="41422" txt_i="29348" txt_f="29349">M</offsets></italic><offsets xml_i="41431" xml_f="41479" txt_i="29349" txt_f="29397"> = 79.16%, SE ± 5.18) compared to time block 1 (</offsets><italic><offsets xml_i="41487" xml_f="41488" txt_i="29397" txt_f="29398">M</offsets></italic><offsets xml_i="41497" xml_f="41539" txt_i="29398" txt_f="29440"> = 84.38%, SE ± 3.76). A significant gum (</offsets><italic><offsets xml_i="41547" xml_f="41548" txt_i="29440" txt_f="29441">F</offsets></italic><offsets xml_i="41557" xml_f="41568" txt_i="29441" txt_f="29452"> = 11.15, d</offsets><italic><offsets xml_i="41576" xml_f="41577" txt_i="29452" txt_f="29453">f</offsets></italic><offsets xml_i="41586" xml_f="41596" txt_i="29453" txt_f="29463"> = 1, 22, </offsets><italic><offsets xml_i="41604" xml_f="41605" txt_i="29463" txt_f="29464">p</offsets></italic><offsets xml_i="41614" xml_f="41654" txt_i="29464" txt_f="29504"> = 0.003) and a gum × drug interaction (</offsets><italic><offsets xml_i="41662" xml_f="41663" txt_i="29504" txt_f="29505">F</offsets></italic><offsets xml_i="41672" xml_f="41683" txt_i="29505" txt_f="29516"> = 10.05, d</offsets><italic><offsets xml_i="41691" xml_f="41692" txt_i="29516" txt_f="29517">f</offsets></italic><offsets xml_i="41701" xml_f="41711" txt_i="29517" txt_f="29527"> = 1, 22, </offsets><italic><offsets xml_i="41719" xml_f="41720" txt_i="29527" txt_f="29528">p</offsets></italic><offsets xml_i="41729" xml_f="41925" txt_i="29528" txt_f="29724"> = 0.004) demonstrated a general enhancing effect of NG (vs. PG) on target detection, which was blocked by KI. Specifically, in the PI conditions, NG significantly elevated % hits relative to PG (</offsets><italic><offsets xml_i="41933" xml_f="41934" txt_i="29724" txt_f="29725">p</offsets></italic><offsets xml_i="41943" xml_f="42019" txt_i="29725" txt_f="29801"> = 0.0001) but this gum effect was not observed under KI conditions (Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="42049" xml_f="42050" txt_i="29801" txt_f="29802">4</offsets></xref><offsets xml_i="42057" xml_f="42304" txt_i="29802" txt_f="30049">). The blockade of nicotine-induced increases in hit rates was further reflected in the comparison of the two NG conditions, where hits during the combined NG-KI condition were significantly reduced compared to when nicotine was combined with PI (</offsets><italic><offsets xml_i="42312" xml_f="42313" txt_i="30049" txt_f="30050">p</offsets></italic><offsets xml_i="42322" xml_f="42331" txt_i="30050" txt_f="30059"> = 0.05) </offsets><italic><offsets xml_i="42339" xml_f="42376" txt_i="30059" txt_f="30096">and when KI was administered alone (p</offsets></italic><offsets xml_i="42385" xml_f="42397" txt_i="30096" txt_f="30105"> &lt; 0.05).</offsets></p><fig id="F4" position="float"><label><offsets xml_i="42438" xml_f="42446" txt_i="30106" txt_f="30114">Figure 4</offsets></label><caption><p><bold><offsets xml_i="42472" xml_f="42624" txt_i="30114" txt_f="30266">Effects of placebo and nicotine gum (collapsed across time blocks, and L-HD and H-HD groups) on mean (± SE)% hits during placebo (PI) and ketamine (KI) </offsets><italic><offsets xml_i="42632" xml_f="42640" txt_i="30266" txt_f="30274">infusion</offsets></italic><offsets xml_i="42649" xml_f="42652" txt_i="30274" txt_f="30277"> (*</offsets><italic><offsets xml_i="42660" xml_f="42661" txt_i="30277" txt_f="30278">p</offsets></italic><offsets xml_i="42670" xml_f="42685" txt_i="30278" txt_f="30290"> &lt; 0.05; ***</offsets><italic><offsets xml_i="42693" xml_f="42694" txt_i="30290" txt_f="30291">p</offsets></italic><offsets xml_i="42703" xml_f="42715" txt_i="30291" txt_f="30300"> &lt; 0.001)</offsets></bold><offsets xml_i="42722" xml_f="42723" txt_i="30300" txt_f="30301">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g004"></graphic></fig><p><offsets xml_i="42798" xml_f="42836" txt_i="30302" txt_f="30340">In a group × gum × block interaction (</offsets><italic><offsets xml_i="42844" xml_f="42845" txt_i="30340" txt_f="30341">F</offsets></italic><offsets xml_i="42854" xml_f="42864" txt_i="30341" txt_f="30351"> = 3.64, d</offsets><italic><offsets xml_i="42872" xml_f="42873" txt_i="30351" txt_f="30352">f</offsets></italic><offsets xml_i="42882" xml_f="42892" txt_i="30352" txt_f="30362"> = 1, 44, </offsets><italic><offsets xml_i="42900" xml_f="42901" txt_i="30362" txt_f="30363">p</offsets></italic><offsets xml_i="42910" xml_f="42961" txt_i="30363" txt_f="30414"> = 0.046), the H-HD group exhibited significantly (</offsets><italic><offsets xml_i="42969" xml_f="42970" txt_i="30414" txt_f="30415">p</offsets></italic><offsets xml_i="42979" xml_f="43040" txt_i="30415" txt_f="30476"> = 0.04) reduced % hits than the L-HD group in time block 1 (</offsets><italic><offsets xml_i="43048" xml_f="43049" txt_i="30476" txt_f="30477">p</offsets></italic><offsets xml_i="43058" xml_f="43092" txt_i="30477" txt_f="30511"> = 0.05) and time block 2 (Figure </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="43122" xml_f="43123" txt_i="30511" txt_f="30512">5</offsets></xref><offsets xml_i="43130" xml_f="43236" txt_i="30512" txt_f="30618">). For the H-HD group, NG (relative to PG) was shown to elevate hit rate in the H-HD during time block 1 (</offsets><italic><offsets xml_i="43244" xml_f="43245" txt_i="30618" txt_f="30619">p</offsets></italic><offsets xml_i="43254" xml_f="43289" txt_i="30619" txt_f="30654"> = 0.006) and during time block 2 (</offsets><italic><offsets xml_i="43297" xml_f="43298" txt_i="30654" txt_f="30655">p</offsets></italic><offsets xml_i="43307" xml_f="43317" txt_i="30655" txt_f="30665"> = 0.001).</offsets></p><fig id="F5" position="float"><label><offsets xml_i="43358" xml_f="43366" txt_i="30666" txt_f="30674">Figure 5</offsets></label><caption><p><bold><offsets xml_i="43392" xml_f="43556" txt_i="30674" txt_f="30838">Effects of placebo and nicotine gum (collapsed across placebo and ketamine infusions) on mean (±SE) % hits of L-HD and H-HD groups in the three times blocks (B1–B3)</offsets></bold><offsets xml_i="43563" xml_f="43567" txt_i="30838" txt_f="30842">. (*</offsets><italic><offsets xml_i="43575" xml_f="43576" txt_i="30842" txt_f="30843">p</offsets></italic><offsets xml_i="43585" xml_f="43600" txt_i="30843" txt_f="30855"> &lt; 0.006; **</offsets><italic><offsets xml_i="43608" xml_f="43609" txt_i="30855" txt_f="30856">p</offsets></italic><offsets xml_i="43618" xml_f="43631" txt_i="30856" txt_f="30866"> &lt; 0.001; </offsets><italic><offsets xml_i="43639" xml_f="43640" txt_i="30866" txt_f="30867">t</offsets></italic><offsets xml_i="43649" xml_f="43651" txt_i="30867" txt_f="30869">, </offsets><italic><offsets xml_i="43659" xml_f="43660" txt_i="30869" txt_f="30870">p</offsets></italic><offsets xml_i="43669" xml_f="43735" txt_i="30870" txt_f="30933"> &lt; 0.05 comparing L-HD and H-HD with placebo gum in B1 and B2).</offsets></p></caption><graphic xlink:href="fphar-03-00172-g005"></graphic></fig><p><offsets xml_i="43810" xml_f="43829" txt_i="30934" txt_f="30953">As shown in Figure </offsets><xref ref-type="fig" rid="F6"><offsets xml_i="43859" xml_f="43860" txt_i="30953" txt_f="30954">6</offsets></xref><offsets xml_i="43867" xml_f="43923" txt_i="30954" txt_f="31010">, FAs were moderated by a gum × time block interaction (</offsets><italic><offsets xml_i="43931" xml_f="43932" txt_i="31010" txt_f="31011">F</offsets></italic><offsets xml_i="43941" xml_f="43951" txt_i="31011" txt_f="31021"> = 3.23, d</offsets><italic><offsets xml_i="43959" xml_f="43960" txt_i="31021" txt_f="31022">f</offsets></italic><offsets xml_i="43969" xml_f="43979" txt_i="31022" txt_f="31032"> = 2, 44, </offsets><italic><offsets xml_i="43987" xml_f="43988" txt_i="31032" txt_f="31033">p</offsets></italic><offsets xml_i="43997" xml_f="44082" txt_i="31033" txt_f="31118"> = 0.032), with NG acting to prevent the response errors seen in time block with PG (</offsets><italic><offsets xml_i="44090" xml_f="44091" txt_i="31118" txt_f="31119">p</offsets></italic><offsets xml_i="44100" xml_f="44110" txt_i="31119" txt_f="31129"> = 0.038).</offsets></p><fig id="F6" position="float"><label><offsets xml_i="44151" xml_f="44159" txt_i="31130" txt_f="31138">Figure 6</offsets></label><caption><p><bold><offsets xml_i="44185" xml_f="44360" txt_i="31138" txt_f="31313">Effects of placebo and nicotine gum (collapsed across placebo and ketamine infusions, and L-HD and H-HD groups) on mean (±SE) % false alarms in the three time blocks (B1–B3; *</offsets><italic><offsets xml_i="44368" xml_f="44369" txt_i="31313" txt_f="31314">p</offsets></italic><offsets xml_i="44378" xml_f="44389" txt_i="31314" txt_f="31322"> &lt; 0.05)</offsets></bold><offsets xml_i="44396" xml_f="44397" txt_i="31322" txt_f="31323">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g006"></graphic></fig><p><offsets xml_i="44472" xml_f="44488" txt_i="31324" txt_f="31340">The analysis of </offsets><italic><offsets xml_i="44496" xml_f="44497" txt_i="31340" txt_f="31341">d</offsets></italic><offsets xml_i="44506" xml_f="44535" txt_i="31341" txt_f="31370">′ yielded a significant gum (</offsets><italic><offsets xml_i="44543" xml_f="44544" txt_i="31370" txt_f="31371">F</offsets></italic><offsets xml_i="44553" xml_f="44564" txt_i="31371" txt_f="31382"> = 13.63, d</offsets><italic><offsets xml_i="44572" xml_f="44573" txt_i="31382" txt_f="31383">f</offsets></italic><offsets xml_i="44582" xml_f="44593" txt_i="31383" txt_f="31394"> = 1, 44, (</offsets><italic><offsets xml_i="44601" xml_f="44602" txt_i="31394" txt_f="31395">p</offsets></italic><offsets xml_i="44611" xml_f="44634" txt_i="31395" txt_f="31418"> = 0.001), drug × gum (</offsets><italic><offsets xml_i="44642" xml_f="44643" txt_i="31418" txt_f="31419">F</offsets></italic><offsets xml_i="44652" xml_f="44662" txt_i="31419" txt_f="31429"> = 7.06, d</offsets><italic><offsets xml_i="44670" xml_f="44671" txt_i="31429" txt_f="31430">f</offsets></italic><offsets xml_i="44680" xml_f="44691" txt_i="31430" txt_f="31441"> = 1, 44, (</offsets><italic><offsets xml_i="44699" xml_f="44700" txt_i="31441" txt_f="31442">p</offsets></italic><offsets xml_i="44709" xml_f="44761" txt_i="31442" txt_f="31494"> = 0.014) and a drug × gum × block × group effects (</offsets><italic><offsets xml_i="44769" xml_f="44770" txt_i="31494" txt_f="31495">F</offsets></italic><offsets xml_i="44779" xml_f="44789" txt_i="31495" txt_f="31505"> = 3.64, d</offsets><italic><offsets xml_i="44797" xml_f="44798" txt_i="31505" txt_f="31506">f</offsets></italic><offsets xml_i="44807" xml_f="44818" txt_i="31506" txt_f="31517"> = 1, 44, (</offsets><italic><offsets xml_i="44826" xml_f="44827" txt_i="31517" txt_f="31518">p</offsets></italic><offsets xml_i="44836" xml_f="44876" txt_i="31518" txt_f="31558"> = 0.05). NG (vs. PG) increased scores (</offsets><italic><offsets xml_i="44884" xml_f="44885" txt_i="31558" txt_f="31559">p</offsets></italic><offsets xml_i="44894" xml_f="44974" txt_i="31559" txt_f="31639"> = 0.001) but this was shown only during PI (not KI) and, as displayed in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="45006" xml_f="45007" txt_i="31639" txt_f="31640">1</offsets></xref><offsets xml_i="45014" xml_f="45067" txt_i="31640" txt_f="31693">, was limited to the H-HD group during time block 1 (</offsets><italic><offsets xml_i="45075" xml_f="45076" txt_i="31693" txt_f="31694">p</offsets></italic><offsets xml_i="45085" xml_f="45102" txt_i="31694" txt_f="31711"> = 0.001) and 2 (</offsets><italic><offsets xml_i="45110" xml_f="45111" txt_i="31711" txt_f="31712">p</offsets></italic><offsets xml_i="45120" xml_f="45173" txt_i="31712" txt_f="31765"> = 0.009). During administration of placebo (PG–PI), </offsets><italic><offsets xml_i="45181" xml_f="45182" txt_i="31765" txt_f="31766">d</offsets></italic><offsets xml_i="45191" xml_f="45294" txt_i="31766" txt_f="31869">′ scores of the H-HD group were also significantly lower than those of the L-HD group in time block 1 (</offsets><italic><offsets xml_i="45302" xml_f="45303" txt_i="31869" txt_f="31870">p</offsets></italic><offsets xml_i="45312" xml_f="45328" txt_i="31870" txt_f="31886"> = 0.05) and 3 (</offsets><italic><offsets xml_i="45336" xml_f="45337" txt_i="31886" txt_f="31887">p</offsets></italic><offsets xml_i="45346" xml_f="45413" txt_i="31887" txt_f="31954"> = 0.05). Also for the H-HD group in the combined Ki-NG condition, </offsets><italic><offsets xml_i="45421" xml_f="45422" txt_i="31954" txt_f="31955">d</offsets></italic><offsets xml_i="45431" xml_f="45488" txt_i="31955" txt_f="32012">′ scores significantly declined from block 1 to block 2 (</offsets><italic><offsets xml_i="45496" xml_f="45497" txt_i="32012" txt_f="32013">p</offsets></italic><offsets xml_i="45506" xml_f="45515" txt_i="32013" txt_f="32022"> = 0.01).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="45563" xml_f="45570" txt_i="32023" txt_f="32030">Table 1</offsets></label><caption><p><bold><offsets xml_i="45596" xml_f="45605" txt_i="32030" txt_f="32039">Mean/±SE </offsets><italic><offsets xml_i="45613" xml_f="45614" txt_i="32039" txt_f="32040">d</offsets></italic><offsets xml_i="45623" xml_f="45707" txt_i="32040" txt_f="32124">′ scores of L-HD and H-HD groups across treatment conditions and time blocks (B1–B3)</offsets></bold><offsets xml_i="45714" xml_f="45715" txt_i="32124" txt_f="32125">.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="45818" xml_f="45827" txt_i="32126" txt_f="32135">Treatment</offsets></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="45875" xml_f="45879" txt_i="32135" txt_f="32139">L-HD</offsets><hr></hr></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="45936" xml_f="45940" txt_i="32139" txt_f="32143">H-HD</offsets><hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46050" xml_f="46052" txt_i="32143" txt_f="32145">B1</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46098" xml_f="46100" txt_i="32145" txt_f="32147">B2</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46146" xml_f="46148" txt_i="32147" txt_f="32149">B3</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46194" xml_f="46196" txt_i="32149" txt_f="32151">B1</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46242" xml_f="46244" txt_i="32151" txt_f="32153">B2</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="46290" xml_f="46292" txt_i="32153" txt_f="32155">B3</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="46362" xml_f="46367" txt_i="32155" txt_f="32160">PG–PI</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46413" xml_f="46422" txt_i="32161" txt_f="32170">3.49/0.18</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46468" xml_f="46477" txt_i="32171" txt_f="32180">3.45/0.27</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46523" xml_f="46532" txt_i="32181" txt_f="32190">3.39/0.28</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46578" xml_f="46587" txt_i="32191" txt_f="32200">3.10/0.18</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46633" xml_f="46642" txt_i="32201" txt_f="32210">3.02/0.27</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46688" xml_f="46697" txt_i="32211" txt_f="32220">2.95/0.28</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="46752" xml_f="46757" txt_i="32221" txt_f="32226">PG–KI</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46803" xml_f="46812" txt_i="32227" txt_f="32236">3.44/0.23</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46858" xml_f="46867" txt_i="32237" txt_f="32246">3.38/0.24</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46913" xml_f="46922" txt_i="32247" txt_f="32256">3.04/0.29</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="46968" xml_f="46977" txt_i="32257" txt_f="32266">3.26/0.23</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47023" xml_f="47032" txt_i="32267" txt_f="32276">3.04/0.24</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47078" xml_f="47087" txt_i="32277" txt_f="32286">3.38/0.29</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="47142" xml_f="47147" txt_i="32287" txt_f="32292">NG–PI</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47193" xml_f="47202" txt_i="32293" txt_f="32302">3.66/0.19</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47248" xml_f="47257" txt_i="32303" txt_f="32312">3.62/0.24</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47303" xml_f="47312" txt_i="32313" txt_f="32322">3.49/0.25</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47358" xml_f="47367" txt_i="32323" txt_f="32332">3.86/0.19</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47413" xml_f="47422" txt_i="32333" txt_f="32342">3.27/0.24</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47468" xml_f="47477" txt_i="32343" txt_f="32352">3.44/0.25</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="47532" xml_f="47537" txt_i="32353" txt_f="32358">NG–KI</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47583" xml_f="47592" txt_i="32359" txt_f="32368">3.46/0.21</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47638" xml_f="47646" txt_i="32369" txt_f="32377">3.23/0.2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47692" xml_f="47701" txt_i="32378" txt_f="32387">3.44/0.25</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47747" xml_f="47756" txt_i="32388" txt_f="32397">3.26/0.21</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47802" xml_f="47811" txt_i="32398" txt_f="32407">3.29/0.22</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="47857" xml_f="47866" txt_i="32408" txt_f="32417">3.05/0.25</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="47908" xml_f="47960" txt_i="32418" txt_f="32470">Response speed was significantly influenced by gum (</offsets><italic><offsets xml_i="47968" xml_f="47969" txt_i="32470" txt_f="32471">F</offsets></italic><offsets xml_i="47978" xml_f="47988" txt_i="32471" txt_f="32481"> = 4.77, d</offsets><italic><offsets xml_i="47996" xml_f="47997" txt_i="32481" txt_f="32482">f</offsets></italic><offsets xml_i="48006" xml_f="48016" txt_i="32482" txt_f="32492"> = 1, 22, </offsets><italic><offsets xml_i="48024" xml_f="48025" txt_i="32492" txt_f="32493">p</offsets></italic><offsets xml_i="48034" xml_f="48112" txt_i="32493" txt_f="32571"> = 0.040), with NG speeding RT relative to PG. In a group × drug interaction (</offsets><italic><offsets xml_i="48120" xml_f="48121" txt_i="32571" txt_f="32572">F</offsets></italic><offsets xml_i="48130" xml_f="48140" txt_i="32572" txt_f="32582"> = 4.77, d</offsets><italic><offsets xml_i="48148" xml_f="48149" txt_i="32582" txt_f="32583">f</offsets></italic><offsets xml_i="48158" xml_f="48167" txt_i="32583" txt_f="32592"> = 1.22, </offsets><italic><offsets xml_i="48175" xml_f="48176" txt_i="32592" txt_f="32593">p</offsets></italic><offsets xml_i="48185" xml_f="48254" txt_i="32593" txt_f="32662"> = 0.040) RT of the H-HD group was found to be significantly slower (</offsets><italic><offsets xml_i="48262" xml_f="48263" txt_i="32662" txt_f="32663">p</offsets></italic><offsets xml_i="48272" xml_f="48339" txt_i="32663" txt_f="32730"> = 0.032) than the L-HD during administration of PG and PI (Figure </offsets><xref ref-type="fig" rid="F7"><offsets xml_i="48369" xml_f="48370" txt_i="32730" txt_f="32731">7</offsets></xref><offsets xml_i="48377" xml_f="48426" txt_i="32731" txt_f="32780">). Although not affecting the H-HD participants, </offsets><italic><offsets xml_i="48434" xml_f="48455" txt_i="32780" txt_f="32801">there was a trend for</offsets></italic><offsets xml_i="48464" xml_f="48477" txt_i="32801" txt_f="32814"> KI (vs. PI) </offsets><italic><offsets xml_i="48485" xml_f="48492" txt_i="32814" txt_f="32821">to slow</offsets></italic><offsets xml_i="48501" xml_f="48506" txt_i="32821" txt_f="32826"> RT (</offsets><italic><offsets xml_i="48514" xml_f="48515" txt_i="32826" txt_f="32827">p</offsets></italic><offsets xml_i="48524" xml_f="48645" txt_i="32827" txt_f="32948"> = 0.06) in the L-HD group, and during the KI condition there were no differences in RT between the L-HD and H-HD groups.</offsets></p><fig id="F7" position="float"><label><offsets xml_i="48686" xml_f="48694" txt_i="32949" txt_f="32957">Figure 7</offsets></label><caption><p><bold><offsets xml_i="48720" xml_f="48891" txt_i="32957" txt_f="33128">Effects of placebo and nicotine gum (collapsed across placebo and ketamine infusions and the three time blocks) on mean (±SE) reaction time (RT) in L-HD and H-HD groups (*</offsets><italic><offsets xml_i="48899" xml_f="48900" txt_i="33128" txt_f="33129">p</offsets></italic><offsets xml_i="48909" xml_f="48920" txt_i="33129" txt_f="33137"> &lt; 0.05)</offsets></bold><offsets xml_i="48927" xml_f="48928" txt_i="33137" txt_f="33138">.</offsets></p></caption><graphic xlink:href="fphar-03-00172-g007"></graphic></fig></sec><sec><title><offsets xml_i="49018" xml_f="49030" txt_i="33140" txt_f="33152">Correlations</offsets></title><p><italic><offsets xml_i="49049" xml_f="49278" txt_i="33153" txt_f="33382">No significant correlations were observed between MMN and d′ in the placebo condition (PG–PI) nor were there any significant correlations between ketamine/nicotine-induced changes in MMN and ketamine/nicotine-induced change in d′</offsets></italic><offsets xml_i="49287" xml_f="49288" txt_i="33382" txt_f="33383">.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="49338" xml_f="49348" txt_i="33386" txt_f="33396">Discussion</offsets></title><p><offsets xml_i="49359" xml_f="50304" txt_i="33397" txt_f="34342">To our knowledge, this is the first study to investigate the moderating role of nicotine on ketamine-induced changes in both sensory and attentional processing, two domains which are highly dysfunctional in schizophrenia and are differentially modulated by the NMDAR antagonist ketamine and the nAChR agonist nicotine. Specifically, the study investigated the hypothesis that MMN – an index of auditory sensory memory that depends on intact NMDAR functioning, would be impaired by ketamine but not when co-administered with nicotine. The results support this hypothesis in that healthy volunteers, assessed to be more prone to experiencing hallucinatory activity (H-HD), evidenced a significantly diminished MMN generation with ketamine alone but not when ketamine was combined with nicotine. During ketamine infusion, MMN amplitudes of H-HD participants were significantly reduced compared to L-HD participants, assessed to be less prone to HD.</offsets></p><p><offsets xml_i="50311" xml_f="50371" txt_i="34343" txt_f="34403">Although not observed in one previous study (Oranje et al., </offsets><xref ref-type="bibr" rid="B94"><offsets xml_i="50403" xml_f="50407" txt_i="34403" txt_f="34407">2000</offsets></xref><offsets xml_i="50414" xml_f="50614" txt_i="34407" txt_f="34607">), the reduction of MMN with intravenous ketamine is consistent with prior reports of MMN attenuation in healthy volunteers with sub-anesthetic doses of the NMDA antagonist ketamine (Umbricht et al., </offsets><xref ref-type="bibr" rid="B128"><offsets xml_i="50647" xml_f="50651" txt_i="34607" txt_f="34611">2000</offsets></xref><offsets xml_i="50658" xml_f="50791" txt_i="34611" txt_f="34744">) and parallels the reduction of MMN in monkeys following infusion of NMDAR antagonists into primary auditory cortex (Javitt et al., </offsets><xref ref-type="bibr" rid="B51"><offsets xml_i="50823" xml_f="50827" txt_i="34744" txt_f="34748">1992</offsets></xref><offsets xml_i="50834" xml_f="50836" txt_i="34748" txt_f="34750">, </offsets><xref ref-type="bibr" rid="B53"><offsets xml_i="50868" xml_f="50872" txt_i="34750" txt_f="34754">1994</offsets></xref><offsets xml_i="50879" xml_f="50881" txt_i="34754" txt_f="34756">, </offsets><xref ref-type="bibr" rid="B52"><offsets xml_i="50913" xml_f="50917" txt_i="34756" txt_f="34760">1996</offsets></xref><offsets xml_i="50924" xml_f="51112" txt_i="34760" txt_f="34948">) as well as the dose-dependent blockade of the MMN recorded from rat auditory cortex after intra-peritoneal injections of the NMDAR antagonist, MK-P01, and memantine (Tikhonravov et al., </offsets><xref ref-type="bibr" rid="B122"><offsets xml_i="51145" xml_f="51149" txt_i="34948" txt_f="34952">2008</offsets></xref><offsets xml_i="51156" xml_f="51158" txt_i="34952" txt_f="34954">, </offsets><xref ref-type="bibr" rid="B123"><offsets xml_i="51191" xml_f="51195" txt_i="34954" txt_f="34958">2010</offsets></xref><offsets xml_i="51202" xml_f="51333" txt_i="34958" txt_f="35089">). Together with the observation of robust reductions of MMN (effect size of 0.99) in schizophrenia patients (Umbricht and Krljes, </offsets><xref ref-type="bibr" rid="B127"><offsets xml_i="51366" xml_f="51370" txt_i="35089" txt_f="35093">2005</offsets></xref><offsets xml_i="51377" xml_f="51529" txt_i="35093" txt_f="35245">) and the wealth of evidence suggesting that psychosis is secondary to NMDAR hypofunction with a downstream effect in dopaminergic activity (Fu et al., </offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="51561" xml_f="51565" txt_i="35245" txt_f="35249">2000</offsets></xref><offsets xml_i="51572" xml_f="51586" txt_i="35249" txt_f="35263">; Lin et al., </offsets><xref ref-type="bibr" rid="B77"><offsets xml_i="51618" xml_f="51622" txt_i="35263" txt_f="35267">2012</offsets></xref><offsets xml_i="51629" xml_f="51897" txt_i="35267" txt_f="35535">), these present findings provide indirect evidence supporting the glutamate/NMDAR hypothesis of schizophrenia and specifically reinforce the implication that deficits in glutamatergic signaling underlie auditory sensory memory impairment characterizing this disorder.</offsets></p><p><offsets xml_i="51904" xml_f="52249" txt_i="35536" txt_f="35881">Unlike previous cognitive and MMN studies that purposefully used ketamine doses which were psychotomimetic (i.e., typically involving initial loading dose of ∼0.25 mg/kg followed by a maintenance dose of ∼0.5–0.9 mg/kg/h) and transiently reproduced schizophrenia-like negative and positive symptoms in healthy volunteers (e.g., Newcomer et al., </offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="52281" xml_f="52285" txt_i="35881" txt_f="35885">1999</offsets></xref><offsets xml_i="52292" xml_f="52583" txt_i="35885" txt_f="36176">), this present study used a single, low dose bolus infusion (0.04 mg/kg) which had previously been shown to induce only mild subjective arousal and euphoric but not clinically relevant behavioral changes. MMN is indirectly proportional to the prevalence of negative symptoms (Urban et al., </offsets><xref ref-type="bibr" rid="B130"><offsets xml_i="52616" xml_f="52620" txt_i="36176" txt_f="36180">2007</offsets></xref><offsets xml_i="52627" xml_f="53000" txt_i="36180" txt_f="36553">) and as such, ketamine-induced behavioral effects with psychotomimetic doses may potentially contribute to cognitive deficits including sensory processing abnormality. However, in healthy controls administered the psychotomimetic psilocybin (a 5-HT2A agonist), a reduction in MMN was not shown despite the experienced marked behavioral changes (Umbricht and Vollenweider, </offsets><xref ref-type="bibr" rid="B129"><offsets xml_i="53033" xml_f="53037" txt_i="36553" txt_f="36557">1999</offsets></xref><offsets xml_i="53044" xml_f="53153" txt_i="36557" txt_f="36666">). Viewed in the context of previous reports of greater MMN deficits in patients prone to AH (Fisher et al., </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="53185" xml_f="53189" txt_i="36666" txt_f="36670">2008</offsets></xref><offsets xml_i="53196" xml_f="53198" txt_i="36670" txt_f="36672">, </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="53230" xml_f="53234" txt_i="36672" txt_f="36676">2011</offsets></xref><offsets xml_i="53241" xml_f="53243" txt_i="36676" txt_f="36678">, </offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="53275" xml_f="53280" txt_i="36678" txt_f="36683">2012a</offsets></xref><offsets xml_i="53287" xml_f="53288" txt_i="36683" txt_f="36684">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="53320" xml_f="53321" txt_i="36684" txt_f="36685">b</offsets></xref><offsets xml_i="53328" xml_f="53473" txt_i="36685" txt_f="36830">) and of studies showing the magnitude of MMN deficit in patients to be correlated with clinical ratings of hallucinatory behavior (Youn et al., </offsets><xref ref-type="bibr" rid="B136"><offsets xml_i="53506" xml_f="53510" txt_i="36830" txt_f="36834">2003</offsets></xref><offsets xml_i="53517" xml_f="53546" txt_i="36834" txt_f="36863">; see also, Hirayasu et al., </offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="53578" xml_f="53582" txt_i="36863" txt_f="36867">1998</offsets></xref><offsets xml_i="53589" xml_f="53612" txt_i="36867" txt_f="36890"> and Thonnesen et al., </offsets><xref ref-type="bibr" rid="B121"><offsets xml_i="53645" xml_f="53649" txt_i="36890" txt_f="36894">2008</offsets></xref><offsets xml_i="53656" xml_f="53955" txt_i="36894" txt_f="37193">), our finding of diminished MMN generation with a low sub-psychotomimetic dose of ketamine in H-HD (vs. L-HD) participants suggests that glutamatergic neurotransmission in the auditory cortex of individuals with a trait that predisposes to AH may be more vulnerable to disruption of NDMAR activity.</offsets></p><p><offsets xml_i="53962" xml_f="54096" txt_i="37194" txt_f="37328">Keeping in mind that AHs of non-patients may not be similar to those of psychotic or non-psychotic clinical patients (Daalman et al., </offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="54128" xml_f="54132" txt_i="37328" txt_f="37332">2011</offsets></xref><offsets xml_i="54139" xml_f="54528" txt_i="37332" txt_f="37721">), hallucinations in general are essentially perceptions that arise through an interaction stemming from neural activations and top-down activity. The basic neural signal contributing to a tonic trait-like vulnerability to experience AHs appears to arise from hyperactivation of functional networks involving the auditory cortex that generate aberrant auditory signals (Kuhn and Gallinat, </offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="54560" xml_f="54564" txt_i="37721" txt_f="37725">2010</offsets></xref><offsets xml_i="54571" xml_f="54588" txt_i="37725" txt_f="37742">; Waters et al., </offsets><xref ref-type="bibr" rid="B131"><offsets xml_i="54621" xml_f="54625" txt_i="37742" txt_f="37746">2012</offsets></xref><offsets xml_i="54632" xml_f="55067" txt_i="37746" txt_f="38181">). Although AHs were not formally assessed during the testing sessions, it is possible that NMDAR antagonism induced an abnormality in auditory signaling and increased hallucinating activity, which may have impacted MMN generation. In support of this argument, patients in general exhibit reduced sensory-level processing of auditory input (e.g., diminished auditory acuity, elevated thresholds for tone discrimination; Mathew et al., </offsets><xref ref-type="bibr" rid="B83"><offsets xml_i="55099" xml_f="55103" txt_i="38181" txt_f="38185">1993</offsets></xref><offsets xml_i="55110" xml_f="55128" txt_i="38185" txt_f="38203">; Holcomb et al., </offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="55160" xml_f="55164" txt_i="38203" txt_f="38207">1995</offsets></xref><offsets xml_i="55171" xml_f="55188" txt_i="38207" txt_f="38224">; Strous et al., </offsets><xref ref-type="bibr" rid="B116"><offsets xml_i="55221" xml_f="55225" txt_i="38224" txt_f="38228">1995</offsets></xref><offsets xml_i="55232" xml_f="55249" txt_i="38228" txt_f="38245">; Wexler et al., </offsets><xref ref-type="bibr" rid="B133"><offsets xml_i="55282" xml_f="55286" txt_i="38245" txt_f="38249">1998</offsets></xref><offsets xml_i="55293" xml_f="55314" txt_i="38249" txt_f="38270">; Rabinowicz et al., </offsets><xref ref-type="bibr" rid="B100"><offsets xml_i="55347" xml_f="55351" txt_i="38270" txt_f="38274">2000</offsets></xref><offsets xml_i="55358" xml_f="55467" txt_i="38274" txt_f="38383">); patients with (vs. without) AHs have greater difficulty in sound (speech) discrimination (Hugdahl et al., </offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="55499" xml_f="55503" txt_i="38383" txt_f="38387">2008</offsets></xref><offsets xml_i="55510" xml_f="55603" txt_i="38387" txt_f="38480">), and the temporal cortex evidences both high glutamate levels in patients (Marsman et al., </offsets><xref ref-type="bibr" rid="B81"><offsets xml_i="55635" xml_f="55639" txt_i="38480" txt_f="38484">2011</offsets></xref><offsets xml_i="55646" xml_f="55732" txt_i="38484" txt_f="38570">) and hypofunctional activation in controls during ketamine infusion (Hugdahl et al., </offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="55764" xml_f="55768" txt_i="38570" txt_f="38574">2008</offsets></xref><offsets xml_i="55775" xml_f="56108" txt_i="38574" txt_f="38907">). However, impaired auditory MMN generation during ketamine infusion is unlikely to be related to competing influences resulting from increasing auditory verbal hallucinations as organized AH (i.e., identifiable as speech) as seen in established schizophrenia are rarely observed during a ketamine challenge (Kantrowitz and Javitt, </offsets><xref ref-type="bibr" rid="B54"><offsets xml_i="56140" xml_f="56144" txt_i="38907" txt_f="38911">2010</offsets></xref><offsets xml_i="56151" xml_f="56495" txt_i="38911" txt_f="39255">). Also, any evoked auditory disturbances during ketamine infusion resemble the pattern observed in the early course of schizophrenia and as such, altered auditory processing during a ketamine challenge may be viewed more as a model of prodromal or acute incipient schizophrenia, rather than late, chronic schizophrenia (Kantrowitz and Javitt, </offsets><xref ref-type="bibr" rid="B54"><offsets xml_i="56527" xml_f="56531" txt_i="39255" txt_f="39259">2010</offsets></xref><offsets xml_i="56538" xml_f="56540" txt_i="39259" txt_f="39261">).</offsets></p><p><offsets xml_i="56547" xml_f="57207" txt_i="39262" txt_f="39922">Nicotine alone did not affect MMN but it prevented the MMN attenuation induced with ketamine. Failure to observe enhanced sensory memory processing with nicotine as shown in earlier reports may be related to methodological differences between studies, including dose and route of nicotine administration, stimulus feature and presentation parameters, ERP recording and processing procedures, and composition of participant samples. However, the ability of nicotine to block the NMDAR antagonist actions of ketamine on auditory sensory memory is consistent with findings that acetylcholine is one of the major modulators of auditory cortical activity (Edeline, </offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="57239" xml_f="57243" txt_i="39922" txt_f="39926">2003</offsets></xref><offsets xml_i="57250" xml_f="57265" txt_i="39926" txt_f="39941">; Soto et al., </offsets><xref ref-type="bibr" rid="B114"><offsets xml_i="57298" xml_f="57302" txt_i="39941" txt_f="39945">2006</offsets></xref><offsets xml_i="57309" xml_f="57451" txt_i="39945" txt_f="40087">), with both high (α4β2) and low (α7) nicotine affinity nAChRs being densely, and widely expressed in the auditory pathway (Morley and Happe, </offsets><xref ref-type="bibr" rid="B86"><offsets xml_i="57483" xml_f="57487" txt_i="40087" txt_f="40091">2000</offsets></xref><offsets xml_i="57494" xml_f="57561" txt_i="40091" txt_f="40158">), particularly where thalamocortical inputs terminate (Metherate, </offsets><xref ref-type="bibr" rid="B84"><offsets xml_i="57593" xml_f="57597" txt_i="40158" txt_f="40162">2004</offsets></xref><offsets xml_i="57604" xml_f="57624" txt_i="40162" txt_f="40182">; Bieszczad et al., </offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="57656" xml_f="57660" txt_i="40182" txt_f="40186">2012</offsets></xref><offsets xml_i="57667" xml_f="57669" txt_i="40186" txt_f="40188">).</offsets></p><p><offsets xml_i="57676" xml_f="57946" txt_i="40189" txt_f="40459">The underlying mechanism of nicotine’s protective action is unclear and although it may involve the regulation of sensory processes by tonic release of endogenous acetylcholine at nAChRs, thalamocortical synapses are excitatory and glutamatergic (Kharazia and Weinberg, </offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="57978" xml_f="57982" txt_i="40459" txt_f="40463">1994</offsets></xref><offsets xml_i="57989" xml_f="58228" txt_i="40463" txt_f="40702">). Hence, nicotine blockade of ketamine effects may implicate nicotinic regulation of thalamocortical glutamate release by presynaptic (or preterminal) nAChRs, and possibly nicotinic regulation of GABAergic interneurons (Radcliffe et al., </offsets><xref ref-type="bibr" rid="B101"><offsets xml_i="58261" xml_f="58265" txt_i="40702" txt_f="40706">1999</offsets></xref><offsets xml_i="58272" xml_f="58293" txt_i="40706" txt_f="40727">; Schilström et al., </offsets><xref ref-type="bibr" rid="B109"><offsets xml_i="58326" xml_f="58330" txt_i="40727" txt_f="40731">2000</offsets></xref><offsets xml_i="58337" xml_f="58360" txt_i="40731" txt_f="40754">; Metherate and Hsieh, </offsets><xref ref-type="bibr" rid="B85"><offsets xml_i="58392" xml_f="58396" txt_i="40754" txt_f="40758">2003</offsets></xref><offsets xml_i="58403" xml_f="58419" txt_i="40758" txt_f="40774">; Liang et al., </offsets><xref ref-type="bibr" rid="B76"><offsets xml_i="58451" xml_f="58455" txt_i="40774" txt_f="40778">2008</offsets></xref><offsets xml_i="58462" xml_f="58491" txt_i="40778" txt_f="40807">; Intskirveli and Metherate, </offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="58523" xml_f="58527" txt_i="40807" txt_f="40811">2012</offsets></xref><offsets xml_i="58534" xml_f="58754" txt_i="40811" txt_f="41031">). As an additional or alternative mechanism, nicotinic agonists have also been shown to inhibit NMDAR-mediated cortical currents, possibly by displacing the obligatory NMDAR co-agonist glycine (Flores-Hernandez et al., </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="58786" xml_f="58790" txt_i="41031" txt_f="41035">2009</offsets></xref><offsets xml_i="58797" xml_f="59072" txt_i="41035" txt_f="41310">). Regardless of the mechanism of action, these present study findings of diminished ketamine-induced MMN impairment were observed with a smoking-dose of nicotine, as was the previous finding of nicotine-induced normalization of MMN in schizophrenia patients (Dulude et al., </offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="59104" xml_f="59108" txt_i="41310" txt_f="41314">2010</offsets></xref><offsets xml_i="59115" xml_f="59470" txt_i="41314" txt_f="41669">). Together they provide tentative support for the contention that excessive tobacco use in schizophrenia in patients may be an attempt to correct sensory deficiencies related to dysfunctional nAChR and/or NMDAR systems. The increase in MMN latency with NMDAR antagonism, reported previously by other studies using larger ketamine doses (Umbricht et al., </offsets><xref ref-type="bibr" rid="B128"><offsets xml_i="59503" xml_f="59507" txt_i="41669" txt_f="41673">2000</offsets></xref><offsets xml_i="59514" xml_f="59547" txt_i="41673" txt_f="41706">; Kreitschmann-Andermahr et al., </offsets><xref ref-type="bibr" rid="B64"><offsets xml_i="59579" xml_f="59583" txt_i="41706" txt_f="41710">2001</offsets></xref><offsets xml_i="59590" xml_f="59606" txt_i="41710" txt_f="41726">; Roser et al., </offsets><xref ref-type="bibr" rid="B107"><offsets xml_i="59639" xml_f="59643" txt_i="41726" txt_f="41730">2011</offsets></xref><offsets xml_i="59650" xml_f="59833" txt_i="41730" txt_f="41913">), was not moderated by nicotine, suggesting that nicotine’s protective actions in the human ketamine model are specific to the strength and not the speed of sensory memory processes.</offsets></p><p><offsets xml_i="59840" xml_f="59996" txt_i="41914" txt_f="42070">Performance in the RVIP task was also investigated and was generally found to be enhanced during acute nicotine administration, with both response accuracy </offsets><italic><offsets xml_i="60004" xml_f="60021" txt_i="42070" txt_f="42087">(hit rate and d′)</offsets></italic><offsets xml_i="60030" xml_f="60267" txt_i="42087" txt_f="42324"> and speed (RT) being improved relative to placebo. Indexing sustained attention and working memory aspects of cognition, task performance in CPT paradigms such as RVIP has consistently been impaired both in schizophrenia (Hilti et al., </offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="60299" xml_f="60303" txt_i="42324" txt_f="42328">2010</offsets></xref><offsets xml_i="60310" xml_f="60326" txt_i="42328" txt_f="42344">; Barch et al., </offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="60357" xml_f="60361" txt_i="42344" txt_f="42348">2012</offsets></xref><offsets xml_i="60368" xml_f="60412" txt_i="42348" txt_f="42392">) and tobacco abstaining smokers (Heishman, </offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="60444" xml_f="60448" txt_i="42392" txt_f="42396">1999</offsets></xref><offsets xml_i="60455" xml_f="60540" txt_i="42396" txt_f="42481">). Nicotine has been shown to improve CPT efficiency in schizophrenia (Smith et al., </offsets><xref ref-type="bibr" rid="B113"><offsets xml_i="60573" xml_f="60577" txt_i="42481" txt_f="42485">2006</offsets></xref><offsets xml_i="60584" xml_f="60599" txt_i="42485" txt_f="42500">; Barr et al., </offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="60630" xml_f="60634" txt_i="42500" txt_f="42504">2008</offsets></xref><offsets xml_i="60641" xml_f="60776" txt_i="42504" txt_f="42639">), with attentional improvements in some studies being reported to be selective for non-smoking (vs. smoking) patients (Harris et al., </offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="60808" xml_f="60812" txt_i="42639" txt_f="42643">2004</offsets></xref><offsets xml_i="60819" xml_f="60822" txt_i="42643" txt_f="42646">). </offsets><italic><offsets xml_i="60830" xml_f="61081" txt_i="42646" txt_f="42897">For sustained attention measured with RVIP, nicotine improved but did not normalize performance in schizophrenia and it exerted no significant reversal of the impaired frontal-parietal-cingulate-thalamic attention network associated with schizophrenia</offsets></italic><offsets xml_i="61090" xml_f="61105" txt_i="42897" txt_f="42912"> (Hong et al., </offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="61137" xml_f="61141" txt_i="42912" txt_f="42916">2011</offsets></xref><offsets xml_i="61148" xml_f="61485" txt_i="42916" txt_f="43253">). Although typically viewed as a task of sustained attention, RVIP also involves a significant working memory component and nicotine improvement of RVIP and attention-dependent tasks may be related to its demonstrated ability to activate posterior (parietal) brain areas traditionally associated with visual attention (Lawrence et al., </offsets><xref ref-type="bibr" rid="B72"><offsets xml_i="61517" xml_f="61521" txt_i="43253" txt_f="43257">2002</offsets></xref><offsets xml_i="61528" xml_f="61636" txt_i="43257" txt_f="43365">) and/or to increase functional connectivity in frontal, executive-based cortical regions (Jacobsen et al., </offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="61668" xml_f="61672" txt_i="43365" txt_f="43369">2004</offsets></xref><offsets xml_i="61679" xml_f="61681" txt_i="43369" txt_f="43371">).</offsets></p><p><offsets xml_i="61688" xml_f="61715" txt_i="43372" txt_f="43399">The increased hit rate and </offsets><italic><offsets xml_i="61723" xml_f="61724" txt_i="43399" txt_f="43400">d</offsets></italic><offsets xml_i="61733" xml_f="62010" txt_i="43400" txt_f="43677">′ seen with nicotine (vs. placebo) gum during placebo infusion was absent when nicotine was administered with ketamine. Ionotropic- but not metabotropic-glutamate antagonist treatment also blocked nicotine improved response accuracy in rodent attentional tasks (Quarta et al., </offsets><xref ref-type="bibr" rid="B98"><offsets xml_i="62042" xml_f="62046" txt_i="43677" txt_f="43681">2007</offsets></xref><offsets xml_i="62053" xml_f="62074" txt_i="43681" txt_f="43702">; Amitai and Markou, </offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="62105" xml_f="62109" txt_i="43702" txt_f="43706">2009</offsets></xref><offsets xml_i="62116" xml_f="62375" txt_i="43706" txt_f="43965">). Together these observations suggest that nAChR modulation of glutamate release underlies nicotine-enhanced target detection and is diminished by NMDAR blockade. However, nAChR and NMDAR ligands appear to overlap in their ligand affinities (Aracava et al., </offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="62406" xml_f="62410" txt_i="43965" txt_f="43969">2005</offsets></xref><offsets xml_i="62417" xml_f="62434" txt_i="43969" txt_f="43986">; Plazas et al., </offsets><xref ref-type="bibr" rid="B96"><offsets xml_i="62466" xml_f="62470" txt_i="43986" txt_f="43990">2007</offsets></xref><offsets xml_i="62477" xml_f="62608" txt_i="43990" txt_f="44121">) and as anesthetics are potent inhibitors of presynaptic nAChRs, with ketamine being shown to block α4 β2 nAChRs (Irnaten et al., </offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="62640" xml_f="62644" txt_i="44121" txt_f="44125">2002</offsets></xref><xref ref-type="bibr" rid="B117"><offsets xml_i="62684" xml_f="62688" txt_i="44125" txt_f="44129">2002</offsets></xref><offsets xml_i="62695" xml_f="62799" txt_i="44129" txt_f="44233">), it may have attenuated the nicotinic stimulation required for improvements in correct response rates.</offsets></p><p><offsets xml_i="62806" xml_f="62896" txt_i="44234" txt_f="44324">Nicotine-facilitated target detection was found to vary between HD groups, with increased </offsets><italic><offsets xml_i="62904" xml_f="62905" txt_i="44324" txt_f="44325">d</offsets></italic><offsets xml_i="62914" xml_f="63072" txt_i="44325" txt_f="44483">′ and hit rates during nicotine (vs. placebo) administration being limited to the higher scoring individuals (H-HD), who also exhibited reduced hit rates and </offsets><italic><offsets xml_i="63080" xml_f="63081" txt_i="44483" txt_f="44484">d</offsets></italic><offsets xml_i="63090" xml_f="63323" txt_i="44484" txt_f="44717">′ compared to L-HD participants in the non-drug condition. Although in schizophrenia hallucinators, the reduced activation shown in primary auditory cortex during auditory target detection was not seen in visual cortex (Ford et al., </offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="63355" xml_f="63359" txt_i="44717" txt_f="44721">2009</offsets></xref><offsets xml_i="63366" xml_f="63504" txt_i="44721" txt_f="44859">), recent neurophysiological evidence has pointed to early visual processing deficits in patients who tend to hallucinate (Kayser et al., </offsets><xref ref-type="bibr" rid="B56"><offsets xml_i="63536" xml_f="63540" txt_i="44859" txt_f="44863">2012</offsets></xref><offsets xml_i="63547" xml_f="64004" txt_i="44863" txt_f="45320">). Perhaps extending to healthy controls with a hallucinating propensity, these findings in patient hallucinators suggested a broader early perceptual deficit that extends beyond the auditory modality. The performance improving effect of nicotine on RVIP in H-HD is consistent with previous ERP research showing preferential enhancement in visual (vs. auditory) processing (e.g., increased amplitude of the N100 and P300 ERPs) with smoking/nicotine (Knott, </offsets><xref ref-type="bibr" rid="B58"><offsets xml_i="64036" xml_f="64040" txt_i="45320" txt_f="45324">1989</offsets></xref><offsets xml_i="64047" xml_f="64063" txt_i="45324" txt_f="45340">; Knott et al., </offsets><xref ref-type="bibr" rid="B60"><offsets xml_i="64095" xml_f="64099" txt_i="45340" txt_f="45344">1995</offsets></xref><offsets xml_i="64106" xml_f="64108" txt_i="45344" txt_f="45346">, </offsets><xref ref-type="bibr" rid="B59"><offsets xml_i="64140" xml_f="64144" txt_i="45346" txt_f="45350">1999</offsets></xref><offsets xml_i="64151" xml_f="64171" txt_i="45350" txt_f="45370">; Pritchard et al., </offsets><xref ref-type="bibr" rid="B97"><offsets xml_i="64203" xml_f="64207" txt_i="45370" txt_f="45374">2004</offsets></xref><offsets xml_i="64214" xml_f="64391" txt_i="45374" txt_f="45551">) and it also parallels reports showing nicotine – induced cognitive facilitation to be more prevalent in poorer performing, cognitively deficient populations (Newhouse et al., </offsets><xref ref-type="bibr" rid="B90"><offsets xml_i="64423" xml_f="64427" txt_i="45551" txt_f="45555">2004</offsets></xref><offsets xml_i="64434" xml_f="64436" txt_i="45555" txt_f="45557">).</offsets></p><p><offsets xml_i="64443" xml_f="64824" txt_i="45558" txt_f="45939">The H-HD group were also slower in responding to RVIP targets than the L-HD group but ketamine, not nicotine, influenced response speed only in the L-HD participants, increasing RT relative to placebo. Together with reduced target detection rates, response slowing in non-patient hallucinators support and extend the contention applied to schizophrenia voice-hearers (Ford et al., </offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="64856" xml_f="64860" txt_i="45939" txt_f="45943">2009</offsets></xref><offsets xml_i="64867" xml_f="65279" txt_i="45943" txt_f="46355">), that their auditory cortex may be “turned on” and tonically “tuned in” to internal acoustic information at the cost of processing not only external sounds but on the basis of these findings, external visual input as well. Perhaps reflecting a “floor” effect that prevents further slowing of RT, ketamine-induced slowing was not seen in H-HD and its appearance in L-HD indicates that, as shown with nicotine’s </offsets><italic><offsets xml_i="65287" xml_f="65298" txt_i="46355" txt_f="46366">attentional</offsets></italic><offsets xml_i="65307" xml_f="65334" txt_i="46366" txt_f="46393"> enhancing properties, the </offsets><italic><offsets xml_i="65342" xml_f="65346" txt_i="46393" txt_f="46397">RVIP</offsets></italic><offsets xml_i="65355" xml_f="65438" txt_i="46397" txt_f="46480"> impairing actions of NMDAR blockade in healthy volunteers are baseline dependent. </offsets><italic><offsets xml_i="65446" xml_f="65668" txt_i="46480" txt_f="46702">MMN failed to show any relationship to d′ in the placebo or active conditions. In schizophrenia, MMN has been found to be related and contribute to higher-order cognitive impairments as well as deficits in social cognition</offsets></italic><offsets xml_i="65677" xml_f="65694" txt_i="46702" txt_f="46719"> (Javitt et al., </offsets><xref ref-type="bibr" rid="B50"><offsets xml_i="65726" xml_f="65730" txt_i="46719" txt_f="46723">1995</offsets></xref><offsets xml_i="65737" xml_f="65756" txt_i="46723" txt_f="46742">; Baldeweg et al., </offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="65787" xml_f="65791" txt_i="46742" txt_f="46746">2004</offsets></xref><offsets xml_i="65798" xml_f="65818" txt_i="46746" txt_f="46766">; Sehatpour et al., </offsets><xref ref-type="bibr" rid="B112"><offsets xml_i="65851" xml_f="65855" txt_i="46766" txt_f="46770">2010</offsets></xref><offsets xml_i="65862" xml_f="65877" txt_i="46770" txt_f="46785">; Wynn et al., </offsets><xref ref-type="bibr" rid="B135"><offsets xml_i="65910" xml_f="65914" txt_i="46785" txt_f="46789">2010</offsets></xref><offsets xml_i="65921" xml_f="65924" txt_i="46789" txt_f="46792">). </offsets><italic><offsets xml_i="65932" xml_f="65959" txt_i="46792" txt_f="46819">Unlike our present findings</offsets></italic><offsets xml_i="65968" xml_f="65970" txt_i="46819" txt_f="46821">, </offsets><italic><offsets xml_i="65978" xml_f="66290" txt_i="46821" txt_f="47133">modeling study suggested ketamine reductions in MMN in healthy volunteers to be mediated by changes in short-term plasticity (of “forward” inter-regional connections) of the auditory hierarchy, which significantly correlated with ratings of ketamine-induced impairments in cognition and control (Schmidt et al., </offsets><xref ref-type="bibr" rid="B111"><offsets xml_i="66323" xml_f="66328" txt_i="47133" txt_f="47138">2012b</offsets></xref><offsets xml_i="66335" xml_f="66640" txt_i="47138" txt_f="47443">). Although RVIP may be an exception, re-examination of this task in larger sample of healthy volunteers and patients and with larger doses of nicotine and ketamine may show unique relationships between MMN and sustained attention that are moderated by SZ pathology and/or nicotinic/glutamatergic activity</offsets></italic><offsets xml_i="66649" xml_f="66650" txt_i="47443" txt_f="47444">.</offsets></p><sec><title><offsets xml_i="66666" xml_f="66677" txt_i="47445" txt_f="47456">Limitations</offsets></title><p><offsets xml_i="66688" xml_f="67505" txt_i="47457" txt_f="48274">Methodological weakness in the present study may have moderated the findings and limited the conclusions and implications of this research. First, both nicotine and ketamine were administered as single doses and accordingly, it is not know if the observed results with each drug and their combination are dose-dependent. Second, ketamine was infused as a low bolus dose and the related cognitive findings may be distinct from those observed with the majority of human ketamine studies that have assessed cognition with sustained psychotogenic doses of this drug. Also, blood levels of the two drugs were not assayed to determine bioavailability and the cognitive effects of nicotine administered via slow buccal absorption may not mirror the effects of acute smoking, which delivers rapid nicotine boli to the brain. </offsets><italic><offsets xml_i="67513" xml_f="67524" txt_i="48274" txt_f="48285">Performance</offsets></italic><offsets xml_i="67533" xml_f="67808" txt_i="48285" txt_f="48560"> assessments were also limited and did not encompass the range of information processing deficits that characterize schizophrenia, each of which are valid targets for novel nicotinic and glutamatergic therapies. Finally, the L-HD and H-HD study samples were relatively small </offsets><italic><offsets xml_i="67816" xml_f="67819" txt_i="48560" txt_f="48563">and</offsets></italic><offsets xml_i="67828" xml_f="68116" txt_i="48563" txt_f="48851"> were drawn from a healthy population and although there are advantages to this approach, similar challenge studies are required with healthy surrogate populations (e.g., schizotypal personality disorder, unaffected first-degree relatives of patients) with genetic links to schizophrenia.</offsets></p></sec></sec><sec><title><offsets xml_i="68144" xml_f="68154" txt_i="48854" txt_f="48864">Conclusion</offsets></title><p><offsets xml_i="68165" xml_f="68617" txt_i="48865" txt_f="49317">This study produced novel findings which underscore the potential role of nAChR and NMDAR systems and their interplay in the etiology of core neurocognitive deficits characterizing schizophrenia. The disturbance in sensory and attentional processing evident with a sub-psychotomimetic dose of ketamine reflects the widespread distribution of brain NMDARs and their sensitivity to minimal perturbations in glutamate signaling. Nicotine exhibited strong </offsets><italic><offsets xml_i="68625" xml_f="68646" txt_i="49317" txt_f="49338">attentional enhancing</offsets></italic><offsets xml_i="68655" xml_f="68776" txt_i="49338" txt_f="49459"> properties, which in part were dependent on glutamate neurotransmission and were also evident by its ability to counter </offsets><italic><offsets xml_i="68784" xml_f="68811" txt_i="49459" txt_f="49486">impaired deviance detection</offsets></italic><offsets xml_i="68820" xml_f="68966" txt_i="49486" txt_f="49632"> induced with NMDAR blockade. That these effects were moderated by a hallucinatory trait in a healthy population suggests that nicotine’s sensory-</offsets><italic><offsets xml_i="68974" xml_f="68985" txt_i="49632" txt_f="49643">attentional</offsets></italic><offsets xml_i="68994" xml_f="69147" txt_i="49643" txt_f="49796"> properties and its modulatory effects on NMDAR systems are relevant to neurocognitive deficits in schizophrenia and may be specific to patient subtypes.</offsets></p></sec><sec><title><offsets xml_i="69169" xml_f="69199" txt_i="49798" txt_f="49828">Conflict of Interest Statement</offsets></title><p><offsets xml_i="69210" xml_f="69382" txt_i="49829" txt_f="50001">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</offsets></p></sec></body><back><ack><p>Research supported by Philip Morris USA Inc. and Philip Morris International. Parts of this data have been presented at the 50th Annual Meeting of the Society for Psychophysiological Research in Portland, Oregon from September 29 to October 3, 2010.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adell</surname><given-names>A.</given-names></name><name><surname>Jimenez-Sanchez</surname><given-names>L.</given-names></name><name><surname>Lopez-Gil</surname><given-names>X.</given-names></name><name><surname>Roman</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Is the acute NMDA receptor hyopfunction a valid model of schizophrenia?</article-title>
<source>Schizophr. Bull.</source>
<volume>38</volume>, <fpage>9</fpage>–<lpage>14</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbr133</pub-id><pub-id pub-id-type="pmid">21965469</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amitai</surname><given-names>N.</given-names></name><name><surname>Markou</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>202</volume>, <fpage>275</fpage>–<lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s00213-008-1246-0</pub-id><pub-id pub-id-type="pmid">18618099</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>J.</given-names></name><name><surname>Anderson</surname><given-names>K.</given-names></name><name><surname>Neilsen</surname><given-names>F.</given-names></name><name><surname>Matheasen</surname><given-names>L.</given-names></name><name><surname>Mirzen</surname><given-names>N.</given-names></name></person-group> (<year>2006</year>). <article-title>Nicotine and clozapine selectivity reverse a PCP-induced deficit of PPI in BALB/cBy but not MMRI mice: comparison with risperidone</article-title>. <source>Behav. Brain Res.</source>
<volume>167</volume>, <fpage>118</fpage>–<lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2005.08.023</pub-id><pub-id pub-id-type="pmid">16225935</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aracava</surname><given-names>Y.</given-names></name><name><surname>Pereira</surname><given-names>E.</given-names></name><name><surname>Maelicke</surname><given-names>A.</given-names></name><name><surname>Albuquerque</surname><given-names>E.</given-names></name></person-group> (<year>2005</year>). <article-title>Memantine blocks alpha7 nicotine acetylcholine receptors more potently than N-methyl-D-aspartate receptors in hippocampal neurons</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>312</volume>, <fpage>1195</fpage>–<lpage>1205</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.077172</pub-id><pub-id pub-id-type="pmid">15522999</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldeweg</surname><given-names>T.</given-names></name><name><surname>Klugman</surname><given-names>A.</given-names></name><name><surname>Gruzwliwe</surname><given-names>J.</given-names></name><name><surname>Hirsch</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Mismatch negativity and cognitive impairment in schizophrenia</article-title>. <source>Schizophr. Res.</source>
<volume>69</volume>, <fpage>203</fpage>–<lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2003.09.009</pub-id><pub-id pub-id-type="pmid">15469194</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldeweg</surname><given-names>T.</given-names></name><name><surname>Wong</surname><given-names>D.</given-names></name><name><surname>Stephan</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Nicotinic modulation of hourly auditory sensory memory: evidence from mismatch negativity potentials</article-title>. <source>Int. J. Psychophysiol.</source>
<volume>59</volume>, <fpage>49</fpage>–<lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2005.07.014</pub-id><pub-id pub-id-type="pmid">16313986</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barch</surname><given-names>D.</given-names></name><name><surname>Moore</surname><given-names>H.</given-names></name><name><surname>Nee</surname><given-names>D.</given-names></name><name><surname>Manoach</surname><given-names>D.</given-names></name><name><surname>Luck</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>CNTRCS imaging biomarkers selection: working memory</article-title>. <source>Schizophr. Bull.</source>
<volume>38</volume>, <fpage>43</fpage>–<lpage>52</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbr154</pub-id><pub-id pub-id-type="pmid">22080498</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>R.</given-names></name><name><surname>Culhane</surname><given-names>M.</given-names></name><name><surname>Jubelt</surname><given-names>L.</given-names></name><name><surname>Mufti</surname><given-names>R.</given-names></name><name><surname>Dyer</surname><given-names>M.</given-names></name><name><surname>Weiss</surname><given-names>A.</given-names></name><name><surname>Deckersbach</surname><given-names>T.</given-names></name><name><surname>Kelly</surname><given-names>J.</given-names></name><name><surname>Freudenreich</surname><given-names>O.</given-names></name><name><surname>Goff</surname><given-names>D.</given-names></name><name><surname>Evens</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>The affects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls</article-title>. <source>Neuropsychopharmacology</source>
<volume>3</volume>, <fpage>480</fpage>–<lpage>490</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301423</pub-id><pub-id pub-id-type="pmid">17443126</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>). <source>Bell Object Relations and Reality Testing Inventory</source>. <publisher-loc>Los Angeles, CA</publisher-loc>: <publisher-name>Western Psychological Services</publisher-name></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>M.</given-names></name><name><surname>Billington</surname><given-names>R.</given-names></name><name><surname>Becker</surname><given-names>B.</given-names></name></person-group> (<year>1985</year>). <article-title>Scale for the assessment of reality testing: reliability, validity, and factorial invariance</article-title>. <source>J. Consult. Clin. Psychol.</source>
<volume>553</volume>, <fpage>506</fpage>–<lpage>511</lpage><pub-id pub-id-type="pmid">4031206</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieszczad</surname><given-names>K.</given-names></name><name><surname>Kant</surname><given-names>R.</given-names></name><name><surname>Constantinescu</surname><given-names>C.</given-names></name><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Kauai</surname><given-names>H.</given-names></name><name><surname>Metherate</surname><given-names>R.</given-names></name><name><surname>Weinberger</surname><given-names>N.</given-names></name><name><surname>Mukherjee</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Nicotinic acetylcholine receptors in rat forebrain that bind 18F-Nifene: relating PET imagining, autoradiography, and behaviour</article-title>. <source>Synapse</source>
<volume>66</volume>, <fpage>418</fpage>–<lpage>434</lpage><pub-id pub-id-type="doi">10.1002/syn.21530</pub-id><pub-id pub-id-type="pmid">22213342</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breese</surname><given-names>C. R.</given-names></name><name><surname>Lee</surname><given-names>M. J.</given-names></name><name><surname>Adams</surname><given-names>C. E.</given-names></name><name><surname>Sullivan</surname><given-names>B.</given-names></name><name><surname>Logel</surname><given-names>J.</given-names></name><name><surname>Gillen</surname><given-names>K. M.</given-names></name><name><surname>Marks</surname><given-names>M. J.</given-names></name><name><surname>Collins</surname><given-names>A. C.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia</article-title>. <source>Neuropsychopharmacology</source>
<volume>23</volume>, <fpage>351</fpage>–<lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(00)00121-4</pub-id><pub-id pub-id-type="pmid">10989262</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Souza</surname><given-names>M.</given-names></name><name><surname>Markou</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits</article-title>. <source>Neuropharmacology</source>
<volume>62</volume>, <fpage>1564</fpage>–<lpage>1573</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.044</pub-id><pub-id pub-id-type="pmid">21288470</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daalman</surname><given-names>K.</given-names></name><name><surname>Boks</surname><given-names>M.</given-names></name><name><surname>Dierderen</surname><given-names>K.</given-names></name><name><surname>Weijer</surname><given-names>A.</given-names></name><name><surname>Blom</surname><given-names>J.</given-names></name><name><surname>Kahn</surname><given-names>R.</given-names></name><name><surname>Sommer</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>The same or different? A phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals</article-title>. <source>J. Clin. Psychiatry</source>
<volume>72</volume>, <fpage>320</fpage>–<lpage>3250</lpage><pub-id pub-id-type="doi">10.4088/JCP.09m05797yel</pub-id><pub-id pub-id-type="pmid">21450152</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulude</surname><given-names>L.</given-names></name><name><surname>Labelle</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2010</year>). <article-title>Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia</article-title>. <source>J. Clin. Psychopharmacol.</source>
<volume>30</volume>, <fpage>541</fpage>–<lpage>548</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e3181f0c9c6</pub-id><pub-id pub-id-type="pmid">20814324</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>G.</given-names></name><name><surname>Boeijinga</surname><given-names>P. H.</given-names></name><name><surname>Demazières</surname><given-names>A.</given-names></name><name><surname>Cisterni</surname><given-names>C.</given-names></name><name><surname>Kuchibhatla</surname><given-names>R.</given-names></name><name><surname>Wesnes</surname><given-names>K.</given-names></name><name><surname>Luthringer</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist on cognitive performance and the EEG of young healthy male volunteers</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>191</volume>, <fpage>919</fpage>–<lpage>929</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0675-x</pub-id><pub-id pub-id-type="pmid">17225162</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edeline</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>The thalamo-cortical auditory receptive fields: regulation by the states of vigilance, learning and the neuromodulatory systems</article-title>. <source>Exp. Brain Res.</source>
<volume>153</volume>, <fpage>554</fpage>–<lpage>572</lpage><pub-id pub-id-type="doi">10.1007/s00221-003-1608-0</pub-id><pub-id pub-id-type="pmid">14517594</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleväg</surname><given-names>B.</given-names></name><name><surname>Goldberg</surname><given-names>T.</given-names></name></person-group> (<year>2000</year>). <article-title>Cognitive impairment in schizophrenia as the core of the disorder</article-title>. <source>Crit. Rev. Neurobiol.</source>
<volume>14</volume>, <fpage>1</fpage>–<lpage>21</lpage><pub-id pub-id-type="pmid">11253953</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engeland</surname><given-names>C.</given-names></name><name><surname>Mahoney</surname><given-names>C.</given-names></name><name><surname>Mohr</surname><given-names>E.</given-names></name><name><surname>Ilivitsky</surname><given-names>V.</given-names></name><name><surname>Knott</surname><given-names>V. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Acute nicotine effects on auditory sensory memory in tacrine treated and nontreated patients with Alzheimer’s disease: an event-related potential study</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>72</volume>, <fpage>457</fpage>–<lpage>464</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(02)00711-6</pub-id><pub-id pub-id-type="pmid">11900820</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D.</given-names></name><name><surname>Drobes</surname><given-names>D.</given-names></name></person-group> (<year>2009</year>). <article-title>Nicotine self-medication of cognitive-attentional processing</article-title>. <source>Addict. Biol.</source>
<volume>14</volume>, <fpage>32</fpage>–<lpage>42</lpage><pub-id pub-id-type="doi">10.1111/j.1369-1600.2008.00130.x</pub-id><pub-id pub-id-type="pmid">18855804</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Grant</surname><given-names>B.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Borracci</surname><given-names>G.</given-names></name><name><surname>Labelle</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2011</year>). <article-title>Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified ‘optimal’ multi-feature paradigm</article-title>. <source>Int. J. Psychophysiol.</source>
<volume>81</volume>, <fpage>245</fpage>–<lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2011.06.018</pub-id><pub-id pub-id-type="pmid">21749905</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Labelle</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2008</year>). <article-title>Auditory hallucinations and the mismatch negativity: processing speech and non-speech sounds in schizophrenia</article-title>. <source>Int. J. Psychophysiol.</source>
<volume>70</volume>, <fpage>3</fpage>–<lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2008.04.001</pub-id><pub-id pub-id-type="pmid">18511139</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Labelle</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2012a</year>). <article-title>Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness</article-title>. <source>Schizophr. Res.</source>
<volume>139</volume>, <fpage>237</fpage>–<lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2012.06.004</pub-id><pub-id pub-id-type="pmid">22727705</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Labelle</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2012b</year>). <article-title>Auditory mismatch negativity (MMN) in acutely ill and stable schizophrenia patients with auditory hallucinations</article-title>. <source>Clin. Neurophysiol.</source> (in press).</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Scott</surname><given-names>T.</given-names></name><name><surname>Shah</surname><given-names>D.</given-names></name><name><surname>Prise</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>M.</given-names></name><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>2010</year>). <article-title>Light up and see: enhancement of the visual mismatch negativity (vMMN) by nicotine</article-title>. <source>Brain Res.</source>
<volume>1313</volume>, <fpage>162</fpage>–<lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.12.002</pub-id><pub-id pub-id-type="pmid">20006592</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Hernandez</surname><given-names>J.</given-names></name><name><surname>Saigadog</surname><given-names>H.</given-names></name><name><surname>De La Rosa</surname><given-names>V.</given-names></name><name><surname>Avita-Ruiz</surname><given-names>T.</given-names></name><name><surname>Torres-Ramiresz</surname><given-names>O.</given-names></name><name><surname>Lopez-Lopez</surname><given-names>G.</given-names></name><name><surname>Atzori</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Cholinergic direct inhibition of N-methyl-D-aspartate receptor-mediated currents in the rat neocortex</article-title>. <source>Synapse</source>
<volume>63</volume>, <fpage>308</fpage>–<lpage>318</lpage><pub-id pub-id-type="doi">10.1002/syn.20609</pub-id><pub-id pub-id-type="pmid">19140165</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>J. M.</given-names></name><name><surname>Roach</surname><given-names>B. J.</given-names></name><name><surname>Jorgensen</surname><given-names>K. W.</given-names></name><name><surname>Turner</surname><given-names>J. A.</given-names></name><name><surname>Brown</surname><given-names>G. G.</given-names></name><name><surname>Notestine</surname><given-names>R.</given-names></name><name><surname>Bischoff-Grethe</surname><given-names>A.</given-names></name><name><surname>Greve</surname><given-names>D.</given-names></name><name><surname>Wible</surname><given-names>C.</given-names></name><name><surname>Lauriello</surname><given-names>J.</given-names></name><name><surname>Belger</surname><given-names>A.</given-names></name><name><surname>Mueller</surname><given-names>B. A.</given-names></name><name><surname>Calhoun</surname><given-names>V.</given-names></name><name><surname>Preda</surname><given-names>A.</given-names></name><name><surname>Keator</surname><given-names>D.</given-names></name><name><surname>O’Leary</surname><given-names>D. S.</given-names></name><name><surname>Lim</surname><given-names>K. O.</given-names></name><name><surname>Glover</surname><given-names>G.</given-names></name><name><surname>Potkin</surname><given-names>S. G.</given-names></name><collab>FBIRN</collab><name><surname>Mathalon</surname><given-names>D. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Tuning in to the voices: a multisite FMRI study of auditory hallucinations</article-title>. <source>Schizophr. Bull.</source>
<volume>35</volume>, <fpage>58</fpage>–<lpage>66</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbn140</pub-id><pub-id pub-id-type="pmid">18987102</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Matta</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Brower</surname><given-names>V.</given-names></name><name><surname>Sharp</surname><given-names>B.</given-names></name></person-group> (<year>2000</year>). <article-title>Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral area</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>294</volume>, <fpage>458</fpage>–<lpage>465</lpage><pub-id pub-id-type="pmid">10900219</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Stimulating the development of drug treatments to improve cognition in schizophrenia</article-title>. <source>Annu. Rev. Clin. Psychol.</source>
<volume>3</volume>, <fpage>159</fpage>–<lpage>180</lpage><pub-id pub-id-type="doi">10.1146/annurev.clinpsy.3.022806.091529</pub-id><pub-id pub-id-type="pmid">17716052</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunduz-Bruce</surname><given-names>H.</given-names></name><name><surname>Reinhart</surname><given-names>R.</given-names></name><name><surname>Roach</surname><given-names>B.</given-names></name><name><surname>Gueorguieva</surname><given-names>R.</given-names></name><name><surname>Oliver</surname><given-names>S.</given-names></name><name><surname>D’Souza</surname><given-names>D.</given-names></name><name><surname>Ford</surname><given-names>J.</given-names></name><name><surname>Krystal</surname><given-names>J.</given-names></name><name><surname>Mathalon</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Glutamatergic modulation of auditory information processing in the human brain</article-title>. <source>Biol. Psychiatry</source>
<volume>71</volume>, <fpage>969</fpage>–<lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.09.031</pub-id><pub-id pub-id-type="pmid">22036036</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkrider</surname><given-names>D.</given-names></name><name><surname>Hedrick</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Acute effects of nicotine on auditory gating in smokers and non-smokers</article-title>. <source>Hear. Res.</source>
<volume>202</volume>, <fpage>114</fpage>–<lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.heares.2004.11.009</pub-id><pub-id pub-id-type="pmid">15811704</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>J.</given-names></name><name><surname>Kongs</surname><given-names>S.</given-names></name><name><surname>Allensworth</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>L.</given-names></name><name><surname>Tregellas</surname><given-names>J.</given-names></name><name><surname>Sullivan</surname><given-names>B.</given-names></name><name><surname>Zerbe</surname><given-names>G.</given-names></name><name><surname>Freedman</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). <article-title>Effects of nicotine on cognitive deficits in schizophrenia</article-title>. <source>Neuropsychopharmacology</source>
<volume>29</volume>, <fpage>1378</fpage>–<lpage>1385</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300450</pub-id><pub-id pub-id-type="pmid">15138435</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heekeren</surname><given-names>K.</given-names></name><name><surname>Daumann</surname><given-names>J.</given-names></name><name><surname>Neukirch</surname><given-names>A.</given-names></name><name><surname>Stock</surname><given-names>C.</given-names></name><name><surname>Kawohl</surname><given-names>W.</given-names></name><name><surname>Norra</surname><given-names>C.</given-names></name><name><surname>Waberski</surname><given-names>T.</given-names></name><name><surname>Gouzoules-Mayfrank</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Mismatch negativity generators in the human 5HT2A agonist and NMDA model of psychosis</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>199</volume>, <fpage>77</fpage>–<lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00213-008-1129-4</pub-id><pub-id pub-id-type="pmid">18488201</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrichs</surname><given-names>R. W.</given-names></name></person-group> (<year>2005</year>). <article-title>The primacy of cognition in schizophrenia</article-title>. <source>Am. Psychol.</source>
<volume>60</volume>, <fpage>229</fpage>–<lpage>242</lpage><pub-id pub-id-type="doi">10.1037/0003-066X.60.3.229</pub-id><pub-id pub-id-type="pmid">15796677</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heishman</surname><given-names>S.</given-names></name></person-group> (<year>1999</year>). <article-title>Behavioural and cognitive effects of nicotine: relationship to nicotine addiction</article-title>. <source>Nicotine Tob. Res.</source>
<volume>1</volume>(<issue>Suppl. 2</issue>), <fpage>S143</fpage>–<lpage>S147</lpage><pub-id pub-id-type="doi">10.1080/14622299050011971</pub-id><pub-id pub-id-type="pmid">11768172</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heishman</surname><given-names>S.</given-names></name><name><surname>Kleykamp</surname><given-names>B.</given-names></name><name><surname>Singleton</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Meta-analysis of the acute effects of nicotine and smoking on human performance</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>210</volume>, <fpage>453</fpage>–<lpage>469</lpage><pub-id pub-id-type="doi">10.1007/s00213-010-1848-1</pub-id><pub-id pub-id-type="pmid">20414766</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilti</surname><given-names>C.</given-names></name><name><surname>Hilti</surname><given-names>L.</given-names></name><name><surname>Heinemann</surname><given-names>D.</given-names></name><name><surname>Robbins</surname><given-names>T.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><name><surname>Cattapan-Ludewig</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Impaired performance in the rapid visual information task (RVIP) could be an endophenotype of schizophrenia</article-title>. <source>Psychiatry Res.</source>
<volume>177</volume>, <fpage>60</fpage>–<lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2009.12.012</pub-id><pub-id pub-id-type="pmid">20110130</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirayasu</surname><given-names>Y.</given-names></name><name><surname>Potts</surname><given-names>G.</given-names></name><name><surname>O’Donnell</surname><given-names>B.</given-names></name><name><surname>Kwon</surname><given-names>J.</given-names></name><name><surname>Arakaki</surname><given-names>H.</given-names></name><name><surname>Akdag</surname><given-names>S.</given-names></name><name><surname>Levitt</surname><given-names>J.</given-names></name><name><surname>Shenton</surname><given-names>M.</given-names></name><name><surname>McCarley</surname><given-names>R.</given-names></name></person-group> (<year>1998</year>). <article-title>Auditory mismatch negativity in schizophrenia: topographic evaluation with a high density recording montage</article-title>. <source>Am. J. Psychiatry</source>
<volume>155</volume>, <fpage>1281</fpage>–<lpage>1284</lpage><pub-id pub-id-type="pmid">9734556</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holcomb</surname><given-names>H.</given-names></name><name><surname>Ritzl</surname><given-names>F.</given-names></name><name><surname>Medoffi</surname><given-names>D.</given-names></name><name><surname>Nevitt</surname><given-names>J.</given-names></name><name><surname>Gordon</surname><given-names>B.</given-names></name><name><surname>Tamminga</surname><given-names>C.</given-names></name></person-group> (<year>1995</year>). <article-title>Tone discrimination performance in schizophrenia patients and normal volunteers: impact of stimulus presentation levels and frequency differences</article-title>. <source>Psychiatry Res.</source>
<volume>57</volume>, <fpage>75</fpage>–<lpage>82</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(95)02270-7</pub-id><pub-id pub-id-type="pmid">7568562</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>L.</given-names></name><name><surname>Schroeder</surname><given-names>M.</given-names></name><name><surname>Ross</surname><given-names>T.</given-names></name><name><surname>Bucholz</surname><given-names>B.</given-names></name><name><surname>Salmeron</surname><given-names>B.</given-names></name><name><surname>Wonodi</surname><given-names>I.</given-names></name><name><surname>Thaker</surname><given-names>G. K.</given-names></name><name><surname>Stein</surname><given-names>E. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia</article-title>. <source>Schizophr. Res.</source>
<volume>34</volume>, <fpage>416</fpage>–<lpage>425</lpage></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Hugdahl</surname><given-names>K.</given-names></name><name><surname>Lobery</surname><given-names>E.-M.</given-names></name><name><surname>Specht</surname><given-names>K.</given-names></name><name><surname>Steen</surname><given-names>V.</given-names></name><name><surname>van Wageningen</surname><given-names>H.</given-names></name><name><surname>Jorgensen</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>Auditory hallucinations in schizophrenia: the role of cognitive, brain structural and genetic disturbances in the left temporal lobe</article-title>. <conf-name>Front. Hum. Neurosci.</conf-name>
<volume>1</volume>:<fpage>6</fpage><pub-id pub-id-type="doi">10.3389/neuro.09.006.2007</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hukkanen</surname><given-names>J.</given-names></name><name><surname>Jacob</surname><given-names>P.</given-names><suffix>3rd</suffix></name><name><surname>Benowaitz</surname><given-names>N.</given-names></name></person-group> (<year>2005</year>). <article-title>Metabolism and deposition kinetics of nicotine</article-title>. <source>Pharmacol. Rev.</source>
<volume>37</volume>, <fpage>79</fpage>–<lpage>115</lpage><pub-id pub-id-type="doi">10.1124/pr.57.1.3</pub-id><pub-id pub-id-type="pmid">15734728</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inami</surname><given-names>R.</given-names></name><name><surname>Kirino</surname><given-names>E.</given-names></name><name><surname>Inoue</surname><given-names>R.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Nicotine effects on mismatch negativity in schizophrenia patients</article-title>. <source>Neuropsychobiology</source>
<volume>36</volume>, <fpage>64</fpage>–<lpage>72</lpage><pub-id pub-id-type="doi">10.1159/000111536</pub-id><pub-id pub-id-type="pmid">18037816</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inauri</surname><given-names>R.</given-names></name><name><surname>Kirino</surname><given-names>E.</given-names></name><name><surname>Inoue</surname><given-names>R.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name></person-group> (<year>2005</year>). <article-title>Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>80</volume>, <fpage>453</fpage>–<lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2005.01.001</pub-id><pub-id pub-id-type="pmid">15740788</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Intskirveli</surname><given-names>I.</given-names></name><name><surname>Metherate</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Nicotinic neuromodulation in auditory cortex requires XNAPK activation in thalamocortical and intracortical circuits</article-title>. <source>J. Neurophysiol.</source>
<volume>107</volume>, <fpage>2782</fpage>–<lpage>2793</lpage><pub-id pub-id-type="doi">10.1152/jn.01129.2011</pub-id><pub-id pub-id-type="pmid">22357798</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irnaten</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Venkatesan</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>C. K.</given-names></name><name><surname>Chang</surname><given-names>K. S.</given-names></name><name><surname>Andresen</surname><given-names>M. C.</given-names></name><name><surname>Mendelowitz</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>Ketamine inhibits presynaptic and postsynaptic excitation of cardiac parasympathetic neuron in nucleus ambiguous</article-title>. <source>Anesthesiology</source>
<volume>96</volume>, <fpage>667</fpage>–<lpage>674</lpage><pub-id pub-id-type="doi">10.1097/00000542-200203000-00024</pub-id><pub-id pub-id-type="pmid">11873043</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>A.</given-names></name><name><surname>Nesic</surname><given-names>J.</given-names></name><name><surname>Groombridge</surname><given-names>C.</given-names></name><name><surname>Clowry</surname><given-names>O.</given-names></name><name><surname>Rusted</surname><given-names>J.</given-names></name><name><surname>Duka</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking</article-title>. <source>Neuropsychopharmacology</source>
<volume>34</volume>, <fpage>257</fpage>–<lpage>265</lpage><pub-id pub-id-type="doi">10.1038/npp.2008.50</pub-id><pub-id pub-id-type="pmid">18418361</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>L. K.</given-names></name><name><surname>D’Souza</surname><given-names>D. C.</given-names></name><name><surname>Mencl</surname><given-names>W. E.</given-names></name><name><surname>Pugh</surname><given-names>K. R.</given-names></name><name><surname>Skudlarski</surname><given-names>P.</given-names></name><name><surname>Krystal</surname><given-names>J. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Nicotine effects on brain function and functional connectivity in schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>55</volume>, <fpage>850</fpage>–<lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2003.12.023</pub-id><pub-id pub-id-type="pmid">15050867</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Glutamatergic theories of schizophrenia</article-title>. <source>Isr. J. Psychiatry Relat. Sci.</source>
<volume>47</volume>, <fpage>4</fpage>–<lpage>16</lpage><pub-id pub-id-type="pmid">20686195</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D.</given-names></name><name><surname>Doneshka</surname><given-names>P.</given-names></name><name><surname>Grochowski</surname><given-names>D.</given-names></name><name><surname>Ritter</surname><given-names>W.</given-names></name></person-group> (<year>1995</year>). <article-title>Impaired mismatch negativity generation reflects widespread dysfunction of working memory on schizophrenia</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>52</volume>, <fpage>550</fpage>–<lpage>558</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1995.03950190032005</pub-id><pub-id pub-id-type="pmid">7598631</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D.</given-names></name><name><surname>Schroeder</surname><given-names>C.</given-names></name><name><surname>Steinschneider</surname><given-names>M.</given-names></name><name><surname>Arizzo</surname><given-names>J.</given-names></name><name><surname>Vaughan</surname><given-names>H.</given-names></name></person-group> (<year>1992</year>). <article-title>Demonstration of mismatch negativity in the monkey</article-title>. <source>Electroencephalogr. Clin. Neurophysiol.</source>
<volume>83</volume>, <fpage>87</fpage>–<lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(92)90137-7</pub-id><pub-id pub-id-type="pmid">1376671</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D.</given-names></name><name><surname>Steinschneider</surname><given-names>M.</given-names></name><name><surname>Schroeder</surname><given-names>C.</given-names></name><name><surname>Arezzo</surname><given-names>J.</given-names></name></person-group> (<year>1996</year>). <article-title>Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>93</volume>, <fpage>11962</fpage>–<lpage>11967</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.21.11962</pub-id><pub-id pub-id-type="pmid">8876245</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D.</given-names></name><name><surname>Steinschneider</surname><given-names>M.</given-names></name><name><surname>Schroeder</surname><given-names>C.</given-names></name><name><surname>Vaughan</surname><given-names>H.</given-names></name><name><surname>Arezzo</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>). <article-title>Detection of stimulus deviance within primate auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation</article-title>. <source>Brain Res.</source>
<volume>667</volume>, <fpage>192</fpage>–<lpage>200</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)91496-6</pub-id><pub-id pub-id-type="pmid">7697356</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantrowitz</surname><given-names>J.</given-names></name><name><surname>Javitt</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models</article-title>. <source>Clin. Schizophr. Relat. Psychoses</source>
<volume>4</volume>, <fpage>189</fpage>–<lpage>200</lpage><pub-id pub-id-type="doi">10.3371/CSRP.4.3.6</pub-id><pub-id pub-id-type="pmid">20880830</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasai</surname><given-names>K.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><name><surname>Kamio</surname><given-names>S.</given-names></name><name><surname>Nakagome</surname><given-names>K.</given-names></name><name><surname>Iwanami</surname><given-names>A.</given-names></name><name><surname>Fukuda</surname><given-names>M.</given-names></name><name><surname>Yumoto</surname><given-names>M.</given-names></name><name><surname>Itoh</surname><given-names>K.</given-names></name><name><surname>Koshida</surname><given-names>I.</given-names></name><name><surname>Abe</surname><given-names>O.</given-names></name><name><surname>Kato</surname><given-names>N.</given-names></name></person-group> (<year>2002</year>). <article-title>Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenia subjects? An EEG and MEG study</article-title>. <source>Clin. Neurophysiol.</source>
<volume>113</volume>, <fpage>141</fpage>–<lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S1388-2457(01)00710-6</pub-id><pub-id pub-id-type="pmid">11801436</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Kayser</surname><given-names>J.</given-names></name><name><surname>Tenke</surname><given-names>C.</given-names></name><name><surname>Kroppmann</surname><given-names>C.</given-names></name><name><surname>Alschuler</surname><given-names>D.</given-names></name><name><surname>Fekri</surname><given-names>S.</given-names></name><name><surname>Gil</surname><given-names>R.</given-names></name><name><surname>Jarskog</surname><given-names>L.</given-names></name><name><surname>Harkavey-Friedman</surname><given-names>J.</given-names></name><name><surname>Buder</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Auditory hallucinations in schizophrenia are associated with neurophysiological deficits in early visual processing</article-title>. <conf-name>Presented at 67th Annual Meeting of the Society for Biological Psychiatry</conf-name>, <conf-loc>Philadelphia</conf-loc></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharazia</surname><given-names>V.</given-names></name><name><surname>Weinberg</surname><given-names>R.</given-names></name></person-group> (<year>1994</year>). <article-title>Glutamate in thalamic fibres terminating in layer IV of primary sensory cortex</article-title>. <source>J. Neurosci.</source>
<volume>14</volume>, <fpage>6021</fpage>–<lpage>6032</lpage><pub-id pub-id-type="pmid">7931559</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V.</given-names></name></person-group> (<year>1989</year>). <article-title>“Brain event-related potentials in smoking performance research,”</article-title> in <source>Smoking and Human Behaviour</source>, eds <person-group person-group-type="editor"><name><surname>Ney</surname><given-names>T.</given-names></name><name><surname>Gale</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>Chichester</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>), <fpage>93</fpage>–<lpage>114</lpage></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V.</given-names></name><name><surname>Bosman</surname><given-names>M.</given-names></name><name><surname>Mahoney</surname><given-names>C.</given-names></name><name><surname>Ilivitsky</surname><given-names>V.</given-names></name><name><surname>Quirt</surname><given-names>K.</given-names></name></person-group> (<year>1999</year>). <article-title>Transdermal nicotine: single dose effects on mood, EEG, performance and event-related potentials</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>63</volume>, <fpage>253</fpage>–<lpage>261</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(99)00006-4</pub-id><pub-id pub-id-type="pmid">10371654</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V.</given-names></name><name><surname>Hooper</surname><given-names>C.</given-names></name><name><surname>Lusk-Mikkelsen</surname><given-names>S.</given-names></name><name><surname>Kerr</surname><given-names>C.</given-names></name></person-group> (<year>1995</year>). <article-title>“Aspects of brain electric event-related potential (ERP) topography related to cigarette smoking, attention, cognition and psychopathology,”</article-title> in <source>Brain Imaging of Nicotine and Tobacco Smoking</source>, ed. <person-group person-group-type="editor"><name><surname>Domino</surname><given-names>E.</given-names></name></person-group> (<publisher-loc>Ann Arbor, MI</publisher-loc>: <publisher-name>NPP Books</publisher-name>), <fpage>191</fpage>–<lpage>221</lpage></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V.</given-names></name><name><surname>McIntosh</surname><given-names>J.</given-names></name><name><surname>Millar</surname><given-names>A.</given-names></name><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Villeneuve</surname><given-names>C.</given-names></name><name><surname>Ilivitsky</surname><given-names>V.</given-names></name><name><surname>Horn</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Nicotine and smoker status moderate brain electric and mood activation induced by ketamine and N-methyl-D-aspartate (NMDA) antagonist</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>85</volume>, <fpage>228</fpage>–<lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2006.08.005</pub-id><pub-id pub-id-type="pmid">17023037</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V.</given-names></name><name><surname>Millar</surname><given-names>A.</given-names></name><name><surname>McIntosh</surname><given-names>J.</given-names></name><name><surname>Shah</surname><given-names>D.</given-names></name><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Blais</surname><given-names>C.</given-names></name><name><surname>Ilivitsky</surname><given-names>V.</given-names></name><name><surname>Horn</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Separate and combined effects of low dose ketamine and nicotine in behavioural and neural correlates of sustained attention</article-title>. <source>Biol. Psychol.</source>
<volume>88</volume>, <fpage>83</fpage>–<lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.biopsycho.2011.06.012</pub-id><pub-id pub-id-type="pmid">21742012</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koychev</surname><given-names>I.</given-names></name><name><surname>Barkus</surname><given-names>E.</given-names></name><name><surname>Ettinger</surname><given-names>V.</given-names></name><name><surname>Killcross</surname><given-names>S.</given-names></name><name><surname>Roiser</surname><given-names>J.</given-names></name><name><surname>Wilkinson</surname><given-names>L.</given-names></name><name><surname>Deakin</surname><given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia</article-title>. <source>J. Psychopharmacol. (Oxford)</source>
<volume>25</volume>, <fpage>1207</fpage>–<lpage>1225</lpage><pub-id pub-id-type="doi">10.1177/0269881111414450</pub-id><pub-id pub-id-type="pmid">21994315</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitschmann-Andermahr</surname><given-names>I.</given-names></name><name><surname>Rosburg</surname><given-names>T.</given-names></name><name><surname>Demme</surname><given-names>U.</given-names></name><name><surname>Gaser</surname><given-names>E.</given-names></name><name><surname>Nowak</surname><given-names>H.</given-names></name><name><surname>Javer</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Effect of ketamine on the neuromagnetic mismatch field in healthy humans</article-title>. <source>Brain Res. Cogn. Brain Res.</source>
<volume>12</volume>, <fpage>109</fpage>–<lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0926-6410(01)00043-X</pub-id><pub-id pub-id-type="pmid">11489614</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>J. H.</given-names></name><name><surname>Karper</surname><given-names>L. P.</given-names></name><name><surname>Seibyl</surname><given-names>J. P.</given-names></name><name><surname>Freeman</surname><given-names>G. K.</given-names></name><name><surname>Delaney</surname><given-names>R.</given-names></name><name><surname>Bremner</surname><given-names>J. D.</given-names></name><name><surname>Heninger</surname><given-names>G. R.</given-names></name><name><surname>Bowers</surname><given-names>M. B.</given-names><suffix>Jr.</suffix></name><name><surname>Charney</surname><given-names>D. S.</given-names></name></person-group> (<year>1994</year>). <article-title>Subanesthetic effects of noncompetitive NMDA receptor antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>51</volume>, <fpage>199</fpage>–<lpage>214</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950030035004</pub-id><pub-id pub-id-type="pmid">8122957</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>J. H.</given-names></name><name><surname>Perry</surname><given-names>E. B.</given-names><suffix>Jr.</suffix></name><name><surname>Gueorguieva</surname><given-names>R.</given-names></name><name><surname>Belger</surname><given-names>A.</given-names></name><name><surname>Madonick</surname><given-names>S. H.</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name><name><surname>Cooper</surname><given-names>T. B.</given-names></name><name><surname>MacDougall</surname><given-names>L.</given-names></name><name><surname>Abi-Saab</surname><given-names>W.</given-names></name><name><surname>D’Souza</surname><given-names>D. C.</given-names></name></person-group> (<year>2005a</year>). <article-title>Comparative and interaction human psychopharmacologic effects of ketamine and amphetamine</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>62</volume>, <fpage>985</fpage>–<lpage>995</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.62.9.985</pub-id><pub-id pub-id-type="pmid">16143730</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>J. H.</given-names></name><name><surname>Abi-Saab</surname><given-names>W.</given-names></name><name><surname>Perry</surname><given-names>E.</given-names></name><name><surname>D’Souza</surname><given-names>D. C.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Gueorguieva</surname><given-names>R.</given-names></name><name><surname>McDougall</surname><given-names>L.</given-names></name><name><surname>Hunsberger</surname><given-names>T.</given-names></name><name><surname>Belger</surname><given-names>A.</given-names></name><name><surname>Levine</surname><given-names>L.</given-names></name><name><surname>Breier</surname><given-names>A.</given-names></name></person-group> (<year>2005b</year>). <article-title>Preliminary evidence of attenuation of the disruptive effects of NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, 24354340, in healthy human subjects</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>129</volume>, <fpage>303</fpage>–<lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-1982-8</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>S.</given-names></name><name><surname>Gallinat</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Quantitative meta-analyses on state and trait aspects of auditory verbal hallucinations in schizophrenia</article-title>. <source>Schizophr. Bull.</source>
<volume>126</volume>, <fpage>20</fpage>–<lpage>27</lpage></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>V.</given-names></name><name><surname>Postman</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>). <article-title></article-title>. <source>Neurosci. Biobehav. Rev.</source>
<volume>29</volume>, <fpage>1021</fpage>–<lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.02.006</pub-id><pub-id pub-id-type="pmid">15964073</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambe</surname><given-names>E.</given-names></name><name><surname>Picciotto</surname><given-names>M.</given-names></name><name><surname>Aghajanian</surname><given-names>G.</given-names></name></person-group> (<year>2003</year>). <article-title>Nicotine induces glutamate release from thalamacortical terminals in prefrontal cortex</article-title>. <source>Neuropsychopharmacology</source>
<volume>28</volume>, <fpage>216</fpage>–<lpage>225</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300032</pub-id><pub-id pub-id-type="pmid">12589374</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Large</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?</article-title>
<source>J. Psychopharmacol. (Oxford)</source>
<volume>21</volume>, <fpage>283</fpage>–<lpage>301</lpage><pub-id pub-id-type="doi">10.1177/0269881107077712</pub-id><pub-id pub-id-type="pmid">17591656</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>N.</given-names></name><name><surname>Ross</surname><given-names>T.</given-names></name><name><surname>Stein</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>Cognitive mechanisms of nicotine on visual attention</article-title>. <source>Neuron</source>
<volume>36</volume>, <fpage>539</fpage>–<lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)01004-8</pub-id><pub-id pub-id-type="pmid">12408855</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>E.</given-names></name><name><surname>Rezvani</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>“Nicotine-antipsychotic drug interactions and cognitive function,”</article-title> in <source>Neurotransmitter Interactions and Cognitive Functions</source>, ed. <person-group person-group-type="editor"><name><surname>Levin</surname><given-names>E.</given-names></name></person-group> (<publisher-loc>Berlin</publisher-loc>: <publisher-name>Birkhauser Veclas</publisher-name>), <fpage>185</fpage>–<lpage>205</lpage></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>E.</given-names></name><name><surname>Rizabis</surname><given-names>Y.</given-names></name><name><surname>Rezvani</surname><given-names>A.</given-names></name><name><surname>Caldwell</surname><given-names>D.</given-names></name><name><surname>Petro</surname><given-names>A.</given-names></name><name><surname>Getachew</surname><given-names>B.</given-names></name></person-group> (<year>2005</year>). <article-title>Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding</article-title>. <source>Brain Res.</source>
<volume>1041</volume>, <fpage>132</fpage>–<lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2005.01.104</pub-id><pub-id pub-id-type="pmid">15829222</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>E.</given-names></name><name><surname>Sledge</surname><given-names>D.</given-names></name><name><surname>Varvah</surname><given-names>A.</given-names></name><name><surname>Addy</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Ventral hippocampal NMDA blockade and nicotinic effects of memory function</article-title>. <source>Brain Res. Bull.</source>
<volume>61</volume>, <fpage>489</fpage>–<lpage>495</lpage><pub-id pub-id-type="doi">10.1016/S0361-9230(03)00183-7</pub-id><pub-id pub-id-type="pmid">13679247</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>K.</given-names></name><name><surname>Poytress</surname><given-names>B.</given-names></name><name><surname>Weinberger</surname><given-names>N.</given-names></name><name><surname>Metherate</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Nicotinic modulation of tone-evoked responses in auditory cortex reflects the strength of prior auditory learning</article-title>. <source>Neurobiol. Learn. Mem.</source>
<volume>90</volume>, <fpage>138</fpage>–<lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2008.02.006</pub-id><pub-id pub-id-type="pmid">18378471</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.-H.</given-names></name><name><surname>Lane</surname><given-names>H. Y.</given-names></name><name><surname>Tzai</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Glutamate signaling in the pathophysiology of schizophrenia</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>100</volume>, <fpage>665</fpage>–<lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2011.03.023</pub-id><pub-id pub-id-type="pmid">21463651</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macmillan</surname><given-names>M.</given-names></name><name><surname>Creelman</surname><given-names>C.</given-names></name></person-group> (<year>1997</year>). <article-title>d′ plus: A program to calculate accuracy and bias measures from detection and discrimination data</article-title>. <source>Spat. Vis.</source>
<volume>11</volume>, <fpage>141</fpage>–<lpage>143</lpage><pub-id pub-id-type="pmid">18095396</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>A.</given-names></name><name><surname>Pinals</surname><given-names>D.</given-names></name><name><surname>Weingartner</surname><given-names>H.</given-names></name><name><surname>Sirocco</surname><given-names>K.</given-names></name><name><surname>Messar</surname><given-names>C.</given-names></name><name><surname>Pickar</surname><given-names>D.</given-names></name></person-group> (<year>1996</year>). <article-title>NMDA receptor hypofunction and human cognition: the effects of ketamine in healthy volunteers</article-title>. <source>Neuropsychopharmacology</source>
<volume>14</volume>, <fpage>301</fpage>–<lpage>307</lpage><pub-id pub-id-type="doi">10.1016/0893-133X(95)00137-3</pub-id><pub-id pub-id-type="pmid">8703299</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansvelder</surname><given-names>H.</given-names></name><name><surname>van Aerde</surname><given-names>K.</given-names></name><name><surname>Covey</surname><given-names>J. J.</given-names></name><name><surname>Brussaard</surname><given-names>A. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Nicotine modulation of neuronal networks: from receptors to cognition</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>184</volume>, <fpage>292</fpage>–<lpage>305</lpage><pub-id pub-id-type="doi">10.1007/s00213-005-0070-z</pub-id><pub-id pub-id-type="pmid">16001117</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsman</surname><given-names>A.</given-names></name><name><surname>van den Heuvel</surname><given-names>M.</given-names></name><name><surname>Klomp</surname><given-names>D.</given-names></name><name><surname>Kahn</surname><given-names>R.</given-names></name><name><surname>Lujten</surname><given-names>P.</given-names></name><name><surname>Hulsholf Pol</surname><given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>Glutamate in schizophrenia: a focused review and meta-analysis of H-MRS studies</article-title>. <source>Schizophr. Bull.</source> [Epub ahead of print].<pub-id pub-id-type="pmid">21746807</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.</given-names></name><name><surname>Davalos</surname><given-names>D.</given-names></name><name><surname>Kisley</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform</article-title>. <source>Nicotine Tob. Res.</source>
<volume>11</volume>, <fpage>698</fpage>–<lpage>706</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntp052</pub-id><pub-id pub-id-type="pmid">19436039</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>V.</given-names></name><name><surname>Gruzelier</surname><given-names>J.</given-names></name><name><surname>Liddle</surname><given-names>P.</given-names></name></person-group> (<year>1993</year>). <article-title>Lateral asymmetries in auditory acuity distinguish hallucinating from nonhallucinating schizophrenic patients</article-title>. <source>Psychiatry Res.</source>
<volume>46</volume>, <fpage>127</fpage>–<lpage>138</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(93)90015-9</pub-id><pub-id pub-id-type="pmid">8483972</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metherate</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). <article-title>Nicotinic acetylcholine receptors in sensory cortex</article-title>. <source>Learn. Mem.</source>
<volume>11</volume>, <fpage>50</fpage>–<lpage>59</lpage><pub-id pub-id-type="doi">10.1101/lm.69904</pub-id><pub-id pub-id-type="pmid">14747517</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metherate</surname><given-names>R.</given-names></name><name><surname>Hsieh</surname><given-names>C.</given-names></name></person-group> (<year>2003</year>). <article-title>Regulation of glutamate synapses by nicotinic acetylcholine receptors in auditory cortex</article-title>. <source>Neurobiol. Learn. Mem.</source>
<volume>80</volume>, <fpage>285</fpage>–<lpage>290</lpage><pub-id pub-id-type="doi">10.1016/S1074-7427(03)00062-5</pub-id><pub-id pub-id-type="pmid">14521870</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>B.</given-names></name><name><surname>Happe</surname><given-names>H.</given-names></name></person-group> (<year>2000</year>). <article-title>Cholingergic receptors: dual roles in transduction and plasticity</article-title>. <source>Hear. Res.</source>
<volume>147</volume>, <fpage>104</fpage>–<lpage>112</lpage><pub-id pub-id-type="doi">10.1016/S0378-5955(00)00124-6</pub-id><pub-id pub-id-type="pmid">10962177</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R.</given-names></name><name><surname>Kahkonen</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>12</volume>, <fpage>125</fpage>–<lpage>135</lpage><pub-id pub-id-type="doi">10.1017/S1461145708009322</pub-id><pub-id pub-id-type="pmid">18771603</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naatanen</surname><given-names>R.</given-names></name><name><surname>Kujala</surname><given-names>T.</given-names></name><name><surname>Winkler</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses</article-title>. <source>Psychophysiology</source>
<volume>48</volume>, <fpage>4</fpage>–<lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.2010.01114.x</pub-id><pub-id pub-id-type="pmid">20880261</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcomer</surname><given-names>J. W.</given-names></name><name><surname>Farber</surname><given-names>N. B.</given-names></name><name><surname>Jevtovic-Todorovic</surname><given-names>V.</given-names></name><name><surname>Selke</surname><given-names>G.</given-names></name><name><surname>Melson</surname><given-names>A. K.</given-names></name><name><surname>Hershey</surname><given-names>T.</given-names></name><name><surname>Craft</surname><given-names>S.</given-names></name><name><surname>Olney</surname><given-names>J. W.</given-names></name></person-group> (<year>1999</year>). <article-title>Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis</article-title>. <source>Neuropsychopharmacology</source>
<volume>20</volume>, <fpage>106</fpage>–<lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(98)00067-0</pub-id><pub-id pub-id-type="pmid">9885791</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newhouse</surname><given-names>P.</given-names></name><name><surname>Potter</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Effects of nicotinic stimulation on cognitive performance</article-title>. <source>Curr. Opin. Pharmacol.</source>
<volume>4</volume>, <fpage>36</fpage>–<lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2003.11.001</pub-id><pub-id pub-id-type="pmid">15018837</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurnberger</surname><given-names>J. I.</given-names><suffix>Jr.</suffix></name><name><surname>Blehar</surname><given-names>M. C.</given-names></name><name><surname>Kaufmann</surname><given-names>C. A.</given-names></name><name><surname>York-Cooler</surname><given-names>C.</given-names></name><name><surname>Simpson</surname><given-names>S. G.</given-names></name><name><surname>Harkavy-Friedman</surname><given-names>J.</given-names></name><name><surname>Severe</surname><given-names>J. B.</given-names></name><name><surname>Malaspina</surname><given-names>D.</given-names></name><name><surname>Reich</surname><given-names>T.</given-names></name></person-group> (<year>1994</year>). <article-title>Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>51</volume>, <fpage>848</fpage>–<lpage>859</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950110009002</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa</surname><given-names>E.</given-names></name><name><surname>Lasalde-Dominicci</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking</article-title>. <source>Cell. Mol. Neurobiol.</source>
<volume>27</volume>, <fpage>609</fpage>–<lpage>639</lpage><pub-id pub-id-type="doi">10.1007/s10571-007-9149-x</pub-id><pub-id pub-id-type="pmid">17554626</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olincy</surname><given-names>A.</given-names></name><name><surname>Stevens</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Treating schizophrenia symptoms with an a7 nicotinic agonist, from mice to men</article-title>. <source>Biochem. Pharmacol.</source>
<volume>74</volume>, <fpage>1192</fpage>–<lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.07.015</pub-id><pub-id pub-id-type="pmid">17714692</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oranje</surname><given-names>B.</given-names></name><name><surname>van Berckel</surname><given-names>B.</given-names></name><name><surname>Kemmer</surname><given-names>C.</given-names></name><name><surname>van Ree</surname><given-names>J.</given-names></name><name><surname>Kahn</surname><given-names>R.</given-names></name><name><surname>Verbaten</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>The effects of subanaesthetic dose of ketamine on human selective attention</article-title>. <source>Neuropsychopharmacology</source>
<volume>3</volume>, <fpage>293</fpage>–<lpage>302</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(99)00118-9</pub-id><pub-id pub-id-type="pmid">10693157</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overall</surname><given-names>J.</given-names></name><name><surname>Gorham</surname><given-names>D.</given-names></name></person-group> (<year>1962</year>). <article-title>The brief psychiatric rating scale</article-title>. <source>Psychol. Rep.</source>
<volume>10</volume>, <fpage>799</fpage>–<lpage>812</lpage><pub-id pub-id-type="doi">10.2466/pr0.1962.10.3.799</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plazas</surname><given-names>P.</given-names></name><name><surname>Savino</surname><given-names>J.</given-names></name><name><surname>Kracun</surname><given-names>S.</given-names></name><name><surname>Gomez-Casati</surname><given-names>M.</given-names></name><name><surname>Katz</surname><given-names>E.</given-names></name><name><surname>Parsons</surname><given-names>C.</given-names></name><name><surname>Millar</surname><given-names>N.</given-names></name><name><surname>Elgoyhen</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition of the alpha9 alpha10 nicotinic cholinergic receptors neramexane, an open channel blocker of N-methyl-D-aspartate receptors</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>566</volume>, <fpage>11</fpage>–<lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.03.026</pub-id><pub-id pub-id-type="pmid">17466293</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>W.</given-names></name><name><surname>Sokhadze</surname><given-names>E.</given-names></name><name><surname>Houlihan</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Effects of nicotine and smoking on event-related potentials: a review</article-title>. <source>Nicotine Tob. Res.</source>
<volume>6</volume>, <fpage>961</fpage>–<lpage>984</lpage><pub-id pub-id-type="doi">10.1080/14622200412331324848</pub-id><pub-id pub-id-type="pmid">15801570</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quarta</surname><given-names>D.</given-names></name><name><surname>Naylor</surname><given-names>C.</given-names></name><name><surname>Morris</surname><given-names>N.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Genn</surname><given-names>R.</given-names></name><name><surname>Stolermay</surname><given-names>I.</given-names></name></person-group> (<year>2007</year>). <article-title>Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine</article-title>. <source>Neuropharmacology</source>
<volume>53</volume>, <fpage>421</fpage>–<lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2007.05.023</pub-id><pub-id pub-id-type="pmid">17631918</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>B.</given-names></name><name><surname>Brinkmeyer</surname><given-names>J.</given-names></name><name><surname>Mobascher</surname><given-names>A.</given-names></name><name><surname>Nothnagel</surname><given-names>M.</given-names></name><name><surname>Musso</surname><given-names>F.</given-names></name><name><surname>Grunder</surname><given-names>G.</given-names></name><name><surname>Savary</surname><given-names>N.</given-names></name><name><surname>Petrovsky</surname><given-names>N.</given-names></name><name><surname>Frommann</surname><given-names>I.</given-names></name><name><surname>Lennertz</surname><given-names>L.</given-names></name><name><surname>Spreckelmeyer</surname><given-names>K. N.</given-names></name><name><surname>Wienker</surname><given-names>T. F.</given-names></name><name><surname>Dahmen</surname><given-names>N.</given-names></name><name><surname>Thuerauf</surname><given-names>N.</given-names></name><name><surname>Clepce</surname><given-names>M.</given-names></name><name><surname>Kiefer</surname><given-names>F.</given-names></name><name><surname>Majic</surname><given-names>T.</given-names></name><name><surname>Mössner</surname><given-names>R.</given-names></name><name><surname>Maier</surname><given-names>W.</given-names></name><name><surname>Gallinat</surname><given-names>J.</given-names></name><name><surname>Diaz-Lacava</surname><given-names>A.</given-names></name><name><surname>Toliat</surname><given-names>M. R.</given-names></name><name><surname>Thiele</surname><given-names>H.</given-names></name><name><surname>Nürnberg</surname><given-names>P.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Winterer</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>109</volume>, <fpage>6271</fpage>–<lpage>6276</lpage><pub-id pub-id-type="doi">10.1073/pnas.1118051109</pub-id><pub-id pub-id-type="pmid">22451930</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabinowicz</surname><given-names>E.</given-names></name><name><surname>Silipo</surname><given-names>G.</given-names></name><name><surname>Goldman</surname><given-names>R.</given-names></name><name><surname>Javitt</surname><given-names>D.</given-names></name></person-group> (<year>2000</year>). <article-title>Auditory sensory dysfunction in schizophrenia: imprecision or distractibility?</article-title>
<source>Arch. Gen. Psychiatry</source>
<volume>57</volume>, <fpage>1149</fpage>–<lpage>1155</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.57.12.1149</pub-id><pub-id pub-id-type="pmid">11115328</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radcliffe</surname><given-names>K.</given-names></name><name><surname>Fisher</surname><given-names>J.</given-names></name><name><surname>Gray</surname><given-names>R.</given-names></name><name><surname>Dani</surname><given-names>J.</given-names></name></person-group> (<year>1999</year>). <article-title>Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>868</volume>, <fpage>591</fpage>–<lpage>510</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb11332.x</pub-id><pub-id pub-id-type="pmid">10414340</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radek</surname><given-names>R.</given-names></name><name><surname>Kohlhaas</surname><given-names>K.</given-names></name><name><surname>Rueter</surname><given-names>L.</given-names></name><name><surname>Mohler</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists</article-title>. <source>Curr. Pharm. Des.</source>
<volume>16</volume>, <fpage>304</fpage>–<lpage>322</lpage><pub-id pub-id-type="doi">10.2174/138161210790170166</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>B.</given-names></name><name><surname>Perry</surname><given-names>D.</given-names></name><name><surname>O’Neil</surname><given-names>J.</given-names></name><name><surname>Manaye</surname><given-names>K.</given-names></name><name><surname>Tizubis</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of nicotine on sensorimotor gating impairment induced by long term treatment with neurotoxic NMDA antagonism</article-title>. <source>Neurotox. Res.</source>
<volume>13</volume>, <fpage>151</fpage>–<lpage>161</lpage><pub-id pub-id-type="doi">10.1007/BF03033499</pub-id><pub-id pub-id-type="pmid">18522895</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezvani</surname><given-names>A.</given-names></name><name><surname>Kholderbarin</surname><given-names>E.</given-names></name><name><surname>Dawson</surname><given-names>E.</given-names></name><name><surname>Levin</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Nicotine and clozapine effects on attentional performance by the NMDA antagonist dizocilpine in female rats</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>11</volume>, <fpage>63</fpage>–<lpage>70</lpage><pub-id pub-id-type="doi">10.1017/S1461145706007528</pub-id><pub-id pub-id-type="pmid">17295931</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezvani</surname><given-names>A.</given-names></name><name><surname>Levin</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Nicotinic-glutamatergic interactions of attentional performance on an apparent visual signal detection task in female rats</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>465</volume>, <fpage>83</fpage>–<lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(03)01439-0</pub-id><pub-id pub-id-type="pmid">12650836</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>T.</given-names></name><name><surname>Alho</surname><given-names>K.</given-names></name><name><surname>Ilmonlemi</surname><given-names>R.</given-names></name><name><surname>Virtanen</surname><given-names>J.</given-names></name><name><surname>Naatanen</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Separate time behaviours of the temporal and frontal mismatch negativity sources</article-title>. <source>Neuroimage</source>
<volume>12</volume>, <fpage>14</fpage>–<lpage>19</lpage><pub-id pub-id-type="doi">10.1006/nimg.2000.0591</pub-id><pub-id pub-id-type="pmid">10875898</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roser</surname><given-names>P.</given-names></name><name><surname>Hauzsfeiter</surname><given-names>I.</given-names></name><name><surname>Chong</surname><given-names>H.-J.</given-names></name><name><surname>Maler</surname><given-names>C.</given-names></name><name><surname>Kawohl</surname><given-names>W.</given-names></name><name><surname>Norra</surname><given-names>C.</given-names></name><name><surname>Juckel</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>Inhibition of cerebral type I cannabinoids receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia</article-title>. <source>Psychopharmacology (Berl.)</source>
<volume>218</volume>, <fpage>611</fpage>–<lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2352-y</pub-id><pub-id pub-id-type="pmid">21590281</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schall</surname><given-names>U.</given-names></name><name><surname>Catts</surname><given-names>S.</given-names></name><name><surname>Chaturvedi</surname><given-names>S.</given-names></name><name><surname>Liebert</surname><given-names>B.</given-names></name><name><surname>Redenbach</surname><given-names>J.</given-names></name><name><surname>Karayandis</surname><given-names>F.</given-names></name><name><surname>Ward</surname><given-names>P.</given-names></name></person-group> (<year>1998</year>). <article-title>The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and extent-related potential measures</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>1</volume>, <fpage>19</fpage>–<lpage>29</lpage><pub-id pub-id-type="doi">10.1017/S146114579800100X</pub-id><pub-id pub-id-type="pmid">11281941</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilström</surname><given-names>B.</given-names></name><name><surname>Fagerquist</surname><given-names>M. V.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Hertel</surname><given-names>P.</given-names></name><name><surname>Panagis</surname><given-names>G.</given-names></name><name><surname>Nomikos</surname><given-names>G. G.</given-names></name><name><surname>Svensson</surname><given-names>T. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Putative role of presynoptic alpha 7 nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area</article-title>. <source>Synapse</source>
<volume>38</volume>, <fpage>375</fpage>–<lpage>383</lpage><pub-id pub-id-type="doi">10.1002/1098-2396(20001215)38:4&lt;375::AID-SYN2&gt;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">11044884</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>Bachmann</surname><given-names>R.</given-names></name><name><surname>Kometer</surname><given-names>M.</given-names></name><name><surname>Csmor</surname><given-names>P.</given-names></name><name><surname>Stephan</surname><given-names>K.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><name><surname>Voklenweider</surname><given-names>F.</given-names></name></person-group> (<year>2012a</year>). <article-title>Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments</article-title>. <source>Neuropsycho pharmacology</source>
<volume>37</volume>, <fpage>865</fpage>–<lpage>875</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.261</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>Diaconescu</surname><given-names>A.</given-names></name><name><surname>Kometer</surname><given-names>M.</given-names></name><name><surname>Friston</surname><given-names>L.</given-names></name><name><surname>Stephan</surname><given-names>K.</given-names></name><name><surname>Vollenweider</surname><given-names>F.</given-names></name></person-group> (<year>2012b</year>). <article-title>Modeling ketamine effects on synaptic plasticity during the mismatch negativity</article-title>. <source>Cereb. Cortex</source> [Epub ahead of print].</mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehatpour</surname><given-names>L.</given-names></name><name><surname>Higgins</surname><given-names>B.</given-names></name><name><surname>Foxe</surname><given-names>J.</given-names></name><name><surname>Javitt</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Sensory deficits and distributed hierarchical dysfunction in schizophrenia</article-title>. <source>Am. J. Psychiatry</source>
<volume>167</volume>, <fpage>818</fpage>–<lpage>827</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2010.09030338</pub-id><pub-id pub-id-type="pmid">20478875</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>R.</given-names></name><name><surname>Warner-Cohen</surname><given-names>J.</given-names></name><name><surname>Matute</surname><given-names>M.</given-names></name><name><surname>Butler</surname><given-names>E.</given-names></name><name><surname>Kelly</surname><given-names>E.</given-names></name><name><surname>Vaidhyanathaswamy</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Effects of nicotine spray on cognitive function in schizophrenia</article-title>. <source>Neuropsychopharmacology</source>
<volume>31</volume>, <fpage>637</fpage>–<lpage>643</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300881</pub-id><pub-id pub-id-type="pmid">16160711</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>G.</given-names></name><name><surname>Kopell</surname><given-names>N.</given-names></name><name><surname>Sen</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Network architecture, receptive fields, and neuromodulation: computational and functional implications of cholinergic modulation in primary auditory cortex</article-title>. <source>J. Neurophysiol.</source>
<volume>96</volume>, <fpage>2972</fpage>–<lpage>2983</lpage><pub-id pub-id-type="doi">10.1152/jn.00133.2006</pub-id><pub-id pub-id-type="pmid">16899641</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spieleway</surname><given-names>C.</given-names></name><name><surname>Markov</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Strain-specificity in nicotine attraction of phencyclidine-induced disruption of prepulse inhibition in mice and relevance to smoking in schizophrenia patients</article-title>. <source>Behav. Genet.</source>
<volume>34</volume>, <fpage>343</fpage>–<lpage>354</lpage><pub-id pub-id-type="doi">10.1023/B:BEGE.0000017878.75206.fd</pub-id><pub-id pub-id-type="pmid">14990873</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strous</surname><given-names>R.</given-names></name><name><surname>Grochowski</surname><given-names>S.</given-names></name><name><surname>Cowan</surname><given-names>N.</given-names></name><name><surname>Javitt</surname><given-names>D.</given-names></name></person-group> (<year>1995</year>). <article-title>Dysfunctional encoding of auditory information in schizophrenia</article-title>. <source>Schiozphr. Res.</source>
<volume>15</volume>, <fpage>135</fpage><pub-id pub-id-type="doi">10.1016/0920-9964(95)95421-5</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassonyi</surname><given-names>E.</given-names></name><name><surname>Charpantier</surname><given-names>E.</given-names></name><name><surname>Muller</surname><given-names>D.</given-names></name><name><surname>Dumont</surname><given-names>L.</given-names></name><name><surname>Bertrand</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia</article-title>. <source>Brain Res. Bull.</source>
<volume>57</volume>, <fpage>133</fpage>–<lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0361-9230(01)00740-7</pub-id><pub-id pub-id-type="pmid">11849819</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tcheremissine</surname><given-names>O.</given-names></name><name><surname>Castro</surname><given-names>M. A.</given-names></name><name><surname>Gardner</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community health researchers</article-title>. <source>Expert Opin. Investig. Drugs</source>
<volume>21</volume>, <fpage>7</fpage>–<lpage>14</lpage><pub-id pub-id-type="doi">10.1517/13543784.2012.634798</pub-id><pub-id pub-id-type="pmid">22059602</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terry</surname><given-names>A.</given-names></name><name><surname>Rishbrough</surname><given-names>V.</given-names></name><name><surname>Buccafusco</surname><given-names>J.</given-names></name><name><surname>Menzush</surname><given-names>F.</given-names></name></person-group> (<year>2002</year>). <article-title>Effects of (+/−)-4-[[2-(1-methyl-2-pyrrolidinylethyl] thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>301</volume>, <fpage>284</fpage>–<lpage>292</lpage><pub-id pub-id-type="doi">10.1124/jpet.301.1.284</pub-id><pub-id pub-id-type="pmid">11907185</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Winsaver</surname><given-names>P.</given-names></name></person-group> (<year>1986</year>). <article-title>Nicotine can attenuate the disruptive effects of phencyclidine on repeated acquisition in monkeys</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>25</volume>, <fpage>185</fpage>–<lpage>190</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(86)90251-0</pub-id><pub-id pub-id-type="pmid">3749226</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thonnesen</surname><given-names>H.</given-names></name><name><surname>Zryagintsev</surname><given-names>M.</given-names></name><name><surname>Harke</surname><given-names>K.</given-names></name><name><surname>Boers</surname><given-names>F.</given-names></name><name><surname>Danmers</surname><given-names>J.</given-names></name><name><surname>Norra</surname><given-names>C.</given-names></name><name><surname>Mathiak</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Optimized mismatch negativity paradigm effects deficits in schizophrenia patients: a combined EEG and MEG study</article-title>. <source>Biol. Psychol.</source>
<volume>77</volume>, <fpage>205</fpage>–<lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.biopsycho.2007.10.009</pub-id><pub-id pub-id-type="pmid">18060677</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikhonravov</surname><given-names>D.</given-names></name><name><surname>Neuvonen</surname><given-names>T.</given-names></name><name><surname>Pertovaara</surname><given-names>A.</given-names></name><name><surname>Savioja</surname><given-names>K.</given-names></name><name><surname>Ruusuvirta</surname><given-names>T.</given-names></name><name><surname>Naatanen</surname><given-names>R.</given-names></name><name><surname>Carlson</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats</article-title>. <source>Brain Res.</source>
<volume>1203</volume>, <fpage>97</fpage>–<lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2008.02.006</pub-id><pub-id pub-id-type="pmid">18325485</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikhonravov</surname><given-names>D.</given-names></name><name><surname>Neuvonen</surname><given-names>T.</given-names></name><name><surname>Pertovgara</surname><given-names>A.</given-names></name><name><surname>Savioja</surname><given-names>K.</given-names></name><name><surname>Rousuvirta</surname><given-names>T.</given-names></name><name><surname>Naatanen</surname><given-names>R.</given-names></name><name><surname>Carklson</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Dose-related effects of Memantine on a mismatch negativity-like response in anesthetized rats</article-title>. <source>Neuroscience</source>
<volume>167</volume>, <fpage>1175</fpage>–<lpage>1182</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.03.014</pub-id><pub-id pub-id-type="pmid">20298759</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timofeeva</surname><given-names>O.</given-names></name><name><surname>Levin</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia</article-title>. <source>Neuroscience</source>
<volume>195</volume>, <fpage>21</fpage>–<lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.08.038</pub-id><pub-id pub-id-type="pmid">21884762</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D.</given-names></name><name><surname>Javitt</surname><given-names>D.</given-names></name><name><surname>Novak</surname><given-names>G.</given-names></name><name><surname>Bates</surname><given-names>J.</given-names></name><name><surname>Pollack</surname><given-names>S.</given-names></name><name><surname>Lieberman</surname><given-names>J.</given-names></name><name><surname>Kane</surname><given-names>J.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of clozapine and auditory event-related potentials in schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>44</volume>, <fpage>716</fpage>–<lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(97)00524-6</pub-id><pub-id pub-id-type="pmid">9798075</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D.</given-names></name><name><surname>Koller</surname><given-names>R.</given-names></name><name><surname>Vollenweider</surname><given-names>F.</given-names></name><name><surname>Schmid</surname><given-names>L.</given-names></name></person-group> (<year>2002</year>). <article-title>Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers</article-title>. <source>Biol. Psychiatry</source>
<volume>51</volume>, <fpage>400</fpage>–<lpage>406</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(01)01242-2</pub-id><pub-id pub-id-type="pmid">11904134</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D.</given-names></name><name><surname>Krljes</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Mismatch negativity in schizophrenia: a meta-analysis</article-title>. <source>Schizophr. Res.</source>
<volume>76</volume>, <fpage>1</fpage>–<lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2004.12.002</pub-id><pub-id pub-id-type="pmid">15927795</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D.</given-names></name><name><surname>Schmid</surname><given-names>L.</given-names></name><name><surname>Koller</surname><given-names>R.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name><name><surname>Hell</surname><given-names>D.</given-names></name><name><surname>Javitt</surname><given-names>D. C.</given-names></name></person-group> (<year>2000</year>). <article-title>Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Implications for models of cognitive deficits in schizophrenia</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>37</volume>, <fpage>1139</fpage>–<lpage>1147</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.57.12.1139</pub-id><pub-id pub-id-type="pmid">11115327</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D.</given-names></name><name><surname>Vollenweider</surname><given-names>F.</given-names></name></person-group> (<year>1999</year>). <article-title>Effects of the NMDA antagonists and 5-HT2A agonists on generation of MMN in human volunteers [abstract]</article-title>. <source>Biol. Psychiatry</source>
<volume>45</volume>, <fpage>51S</fpage>–<lpage>52S</lpage></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>A.</given-names></name><name><surname>Kremlacek</surname><given-names>J.</given-names></name><name><surname>Libiger</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Mismatch negativity in patients with schizophrenia</article-title>. <source>Acta Medica Cordoba</source>
<volume>50</volume>, <fpage>23</fpage>–<lpage>28</lpage></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>F.</given-names></name><name><surname>Allen</surname><given-names>P.</given-names></name><name><surname>Aleman</surname><given-names>A.</given-names></name><name><surname>Fernyhough</surname><given-names>C.</given-names></name><name><surname>Woodward</surname><given-names>T.</given-names></name><name><surname>Badcock</surname><given-names>J.</given-names></name><name><surname>Barkhaus</surname><given-names>E.</given-names></name><name><surname>Johns</surname><given-names>L.</given-names></name><name><surname>Varese</surname><given-names>F.</given-names></name><name><surname>Menon</surname><given-names>M.</given-names></name><name><surname>Vercammen</surname><given-names>A.</given-names></name><name><surname>Lavoi</surname><given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Auditory hallucinations in schizophrenia and nonschizophrenic populations: a review and integrated model of cognitive mechanisms</article-title>. <source>Schizophr. Bull.</source>
<volume>38</volume>, <fpage>683</fpage>–<lpage>693</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs070</pub-id><pub-id pub-id-type="pmid">22446568</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesnes</surname><given-names>K.</given-names></name><name><surname>Warburton</surname><given-names>D.</given-names></name></person-group> (<year>1984</year>). <article-title>Effects of scopolamine and nicotine on human information processing performance</article-title>. <source>Psychopharmacol.</source>
<volume>82</volume>, <fpage>147</fpage>–<lpage>150</lpage><pub-id pub-id-type="doi">10.1007/BF00427761</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wexler</surname><given-names>B.</given-names></name><name><surname>Stevens</surname><given-names>A.</given-names></name><name><surname>Bowers</surname><given-names>A.</given-names></name><name><surname>Sernyak</surname><given-names>M.</given-names></name><name><surname>Goldman-Rakic</surname><given-names>P.</given-names></name></person-group> (<year>1998</year>). <article-title>Word and tone working memory deficits in schizophrenia</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>55</volume>, <fpage>1093</fpage>–<lpage>1096</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.55.12.1093</pub-id><pub-id pub-id-type="pmid">9862552</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterer</surname><given-names>G.</given-names></name></person-group> (<year>2010</year>). <article-title>Why do patients with schizophrenia smoke?</article-title>
<source>Curr. Opin. Psychiatry</source>
<volume>23</volume>, <fpage>112</fpage>–<lpage>119</lpage><pub-id pub-id-type="doi">10.1097/YCO.0b013e3283366643</pub-id><pub-id pub-id-type="pmid">20051860</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>J.</given-names></name><name><surname>Sugar</surname><given-names>C.</given-names></name><name><surname>Horan</surname><given-names>W.</given-names></name><name><surname>Kem</surname><given-names>R.</given-names></name><name><surname>Green</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Mismatch negativity, social cognition, and functioning in schizophrenia patients</article-title>. <source>Biol. Psychiatry</source>
<volume>67</volume>, <fpage>940</fpage>–<lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2009.11.024</pub-id><pub-id pub-id-type="pmid">20074704</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>H.-J.</given-names></name><name><surname>Kim</surname><given-names>J.-J.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Kwon</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>Altered hemispheric asymmetry and positive symptoms in schizophrenia: equivalent current dipole of auditory mismatch negativity</article-title>. <source>Schizophr. Res.</source>
<volume>59</volume>, <fpage>253</fpage>–<lpage>260</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(02)00154-8</pub-id><pub-id pub-id-type="pmid">12414082</pub-id></mixed-citation></ref></ref-list></back></article>